Prof. Dr. Stefan A. Laufer: Full List of Publications as of May 15, 2026

702	Inhibitors Targeting SARS-CoV-2 Papain-Like Protease: Screening, Design, Synthesis, and Biological Evaluation Elena-Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Correa Verissimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael Victorio Carvalho Guido, Anthony J O'Donoghue, Stefan A Laufer, Thanigaimalai Pillaiyar ChemMedChem 21 (9), e202600007, https://doi.org/10.1002/cmdc.202600007	2026	
701	Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4 Wolfgang Albrecht, Roland Selig, Bent Pfaffenrot, Philip Kloevekorn, Michael Juchum, Stefan Zwirner, Sabrina Klotz, Lars Zender, Stefan Laufer Journal of Medicinal Chemistry, https://doi.org/10.1021/acs.jmedchem.6c00689	2026	
700	Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors Xiaojun Julia Liang, Claudia Albertini, Thales Kronenberger, Ekaterina Shevchenko, Alexander Rasch, Benedict-Tilman Berger, Martin Schwalm, Lena Marie Berger, Ricardo AM Serafim, Michael Forster, Apirat Chaikuad, Maria Laura Bolognesi, Susanne Müller, Antti Poso, Stefan Laufer, Stefan Knapp, Matthias Gehringer https://doi.org/10.26434/chemrxiv.15002582/v1	2026	
699	Atm kinase inhibitors S Laufer, M Forster, L Zender, TT Dimitrov, AA Moschopoulou US Patent App. 19/336,316	2026	
698	New Quinoline Kinase Inhibitors With Good Selectivity for NAK Kinases and Anti-Tumor Activity Against Ewing Sarcoma Caroline de Bem Gentz, Thais Helena Maciel Fernandes, Marcela Silva Lopes, Lewis Elson, Andreas Krämer, Lucas Rodrigo de Souza, Isadora Serraglio Fortes, Geórgia Silva Pinto, Martha Cestari Silva Martins, Henrique Barros de Lima, André da Silva Santiago, Lauro José Gregianin, Katlin Brauer Massirer, Mário Henrique Bengtson, Rafael Roesler, Stefan Knapp, Stefan A Laufer, Saulo Fernandes de Andrade Archiv der Pharmazie 359 (1), e70184, https://doi.org/10.1002/ardp.70184	2026	
697	4-[5-(4-Fluorophenyl)-1, 2-oxazol-4-yl] pyridine P Koch, D Schollmeyer, S Laufer, IUCrData 10 (11), x250987	2025	

696	3-benzoyl-1H-pyrrolo [2, 3-b] pyridine derivatives as MKK4 inhibitors for treating liver diseases R Selig, S Laufer, W Albrecht US Patent 12,466,826	2025	
695	Investigation on LASSBio-1971 and LASSBio-1974 Cellular Cytotoxic Mechanism and Their Comparative DMPK Profile Manoel Oliveira de Moraes Junior, Gisele Barbosa, Caroline Marques Xavier da Costa, Raysa Magali Pillpe-Meza, Wesley Leandro de Gouveia, Daniel Nascimento do Amaral, Luis Gabriel Valdivieso Gelves, Stefan Laufer, Lídia Moreira Lima Archiv der Pharmazie, 358 (11), e70151	2025	
694	Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity P Flury, J Vishwakarma, K Sylvester, N Higashi-Kuwata, AK Dabrowska, R Delgado, A Cuell, R Basu, AB Taylor, EG de Oliveira, MAM Serafim, J Qiao, Y Chen, S Yang, AJ O'Donoghue, H Mitsuya, M Gütschow, SA Laufer, CE Müller, RS Harris, T Pillaiyar Journal of Medicinal Chemistr 68 (18), 19339-19376	2025	
693	Caffeinated and Decaffeinated Yerba Mate (Ilex paraguariensis) Infusion Extracts Alter CD73 and Reduce the Migration and Adhesion of Glioblastoma Cells DR Birkhan, RD Weimer, FM Diz, L de Leon Aguiar, VP Pedroso, VJ Pereira, GS Rocha, EL Pedrazza, **S Laufer**, B Sgarioni, VHS Rodrigues, E Cassel, FB Morrone Plant Foods for Human Nutrition 80 (3), 137	2025	
692	Synergistic Effects of MKK4 Inhibitor and Ex Vivo Gene Therapy on Liver Regeneration in a Porcine Model of FAH Deficiency: Progress Towards Human Liver Production in Chimeric Pigs S Kazeminia, B Ahmadzada, K Hussein, JC Correa, S Wilken, K Ezenekwe, A Schulze, L Zender, **S Laufer**, W Albrecht, L Yngsdal, S Nyberg American Journal of Transplantation 25 (8), S10	2025	
691	Pro-Regenerative Effects of an MKK4 Inhibitor Drug in a Porcine Model of Steatohepatitis SN Wilken, P Felgendreff, SM Hosseiniasl, A Minshew, R Selig, W Albrecht, **S Laufer**, RK Moreira, H Malhi, L Zender, SL Nyberg American Journal of Transplantation 25 (8), S292	2025	
690	Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one MKK4 Inhibitor L Katzengruber, P Sander, S Zwirner, A Rasch, E Eberlein, R Selig, W Albrecht, L Zender, **SA Laufer** Journal of medicinal chemistry 68 (14), 14782-14805	2025	

689	Structure–Activity Relationships of Inactive-Conformation Binding EGFR Inhibitors: Linking the ATP and Allosteric Pockets SP Chitnis, F Wittlinger, M Möllers, TJ Hartman, M Günther, MJ Eck, **SA Laufer**, DE Heppner Archiv der Pharmazie 358 (7), e70027	2025	
688	Computational Discovery and Optimization of a Potent, Selective, and Drug-like Scaffold for p38α Inhibition J Nelen, M Goettert, M Forster, L Breuils, JM Villalgordo-Soto, **SA Laufer,** H Pérez-Sánchez https://doi.org/10.26434/chemrxiv-2025-l8jlq	2025	
687	A "Ligand First" Approach toward Selective, Covalent JNK2/3 Inhibitors VR Wydra, N Plank, S Zwirner, R Selig, A Rasch, B Masberg, M Lämmerhofer, L Zender, P Koch, W Albrecht, **S Laufer** Journal of Medicinal Chemistry, J. Med. 2025, 68, 11, 12004–12028	2025	
686	A patent review of CXCR7 modulators (2019-present) T Pillaiyar, S **Laufer** Expert Opinion on Therapeutic Patents 35 (6), 543-569	2025	
685	An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities N Krüger, SA **Laufer**, T Pillaiyar Drug Discovery Today, 104364	2025	
684	Stress-induced intratumoral senescence matrix shifts cancer evolution towards metastasis O Trompak, SA Schütte, JA Macedo, S Scheuermann, Z Hu, I Minia, A Manukyan, T Kronenberger, M Zago, R Krebs, A Nuernbergk, TW Kang, C Schieler, L Taranets, AM Cuesta, M Forster, K Bieber, W Albrecht, E Rist, C Yurttas, D Dauch, B Weigelin, B Sipos, T Longerich, S Singer, MW Löffler, M Claassen, F Wimmers, M Landthaler, A Königsrainer, S Biskup, S **Laufer**, CM Seitz, S Zender Cancer Research 85 (8_Supplement_1), 6419-6419	2025	
683	Cover Feature: The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit to Lead (ChemMedChem 8/2025) J Quancard, A Bach, C Borsari, R Craft, C Gnamm, SM Guéret, IV Hartung, HF Koolman, S **Laufer**, S Lepri, J Messinger, K Ritter, G Sbardella, A Unzue Lopez, MK Wilwacher, B Cox, RJ Young ChemMedChem 20 (8), e202580804	2025	
682	Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death B Praefke, P Klövekorn, R Selig, W Albrecht, S **Laufer** US Patent 12,264,158	2025	

681	Uncovering α-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies J Galvez B. Pedreira, P Woelffing, M Schwarz, S Ebner, R Rudalska, B Masberg, A Esposito, A Rashidian, E Shevchenko, L Smutna, P Pavek, J Kublbeck, T Kronenberger, L Zender, M Lämmerhofer, D Dauch, SA **Laufer** Journal of Medicinal Chemistry	2025	
680	Uncovering α-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies JGB Pedreira, P Woelffing, M Schwarz, S Ebner, R Rudalska, B Masberg, A Esposito, A Rashidian, E Shevchenko, L Smutna, P Pavek, J Kublbeck, T Kronenberger, L Zender, M Lämmerhofer, D Dauch, SA **Laufer** Journal of medicinal chemistry 68 (7), 7180	2025	
679	Drug Design in Motion: Concepts and Applications of Classical Molecular Dynamics Simulations E Shevchenko, S **Laufer**, A Poso, T Kronenberger Computer-Aided and Machine Learning-Driven Drug Design: From Theory to … ????	2025	
678	Untersuchung der Adressierbarkeit des Cysteinoms der Proteinkinasen durch Kovalente Fragmente G Wang, NJ Seidler, S Röhm, Y Pan, XJ Liang, L Haarer, BT Berger, SA Sivashanmugam, VR Wydra, M Forster, SA **Laufer**, A Chaikuad, M Gehringer, S Knapp Angewandte Chemie 137 (8), e202419736	2025	
677	The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit to Lead J Quancard, A Bach, C Borsari, R Craft, C Gnamm, SM Guéret, IV Hartung, HF Koolmann, S **Laufer**, S Lepri, J Messinger, K Ritter, G Sbardella, A Unzue Lopez, MK Wilwacher, B Cox, RJ Young ChemMedChem, e202400931	2025	
676	An investigation of the drug release kinetics of 3D-Printed two compartment Theophylline and Prednisolone tablets T Pflieger, R Venkatesh, M Dachtler, S **Laufer**, D Lunter International Journal of Pharmaceutics, 125218	2025	
675	First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer R Rudalska, J Harbig, M Forster, P Woelffing, A Esposito, M Kudolo, A Botezatu, V Haller, N Janssen, S Holzmayer, P Nahidino, A Trompak, T Pantsar, T Kronenberger, C Yurttas, E Rist, ANR Weber, MH Dahlke, G Ott, A Koenigsrainer, U Rothbauer, M Maerklin, T Muerdter, M Schwab, S Singer, L Zender, S **Laufer**, D Dauch Nature Cancer, 1-19	2025	

674	Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and Its Variants Displaying Potent Antiviral Activity P Flury, N Krüger, K Sylvester, J Breidenbach, G Al Hamwi, J Qiao, Y Chen, C Rocha, M Sá Magalhaes Serafim, E Barbosa da Silva, S Pöhlmann, A Poso, T Kronenberger, K Rox, AJ O'Donoghue, S Yang, N Sträter, M Gütschow, SA **Laufer**, CE Müller, T Pillaiyar Journal of medicinal chemistry	2025	
673	ACKR3 agonism induces heterodimerization with chemokine receptor CXCR4 and attenuates platelet function V Dicenta-Baunach, Z Laspa, D Schaale, M Sigle, A Bayrak, T Castor, T Pillaiyar, S **Laufer**, MP Gawaz, AK Rohlfing European Journal of Clinical Investigation 55 (1), e14327	2025	
672	Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example P Sander, MP Schwalm, A Krämer, L Elson, A Rasch, B Masberg, R Selig, A Sievers-Engler, M Lämmerhofer, S Müller, S Knapp, W Albrecht, SA **Laufer** Journal of medicinal chemistry 68 (1), 674-694	2024	
671	Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase Inhibitors F Wittlinger, SP Chitnis, CD Pham, T Damghani, KB Patel, M Möllers, IK Schaeffner, OA Abidakun, MQ Deng, BC Ogboo, A Rasch, TS Beyett, B Buckley F Feru, T Shaurova, C Knappe, MJ Eck, PA Hershberger, DA Scott, AL Brandt, SA **Laufer**, DE Heppner Journal of Medicinal Chemistry 67 (23), 21438-21469	2024	
670	Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and its Variants Displaying Potent Antiviral Activity T Pillaiyar, P Flury, N Krüger, K Sylvester, J Breidenbach, G Al Hamwi, J Qiao, Y Chen, C Rocha, M Serafim, E Barbosa da Silva, S Pohlmann, A Poso, T Kronenberger, K Rox, A O'Donoghue, S Yang, N Sträter, M Gütschow, SA **Laufer**, CE Müller ????	2024	
669	Hemin promotes platelet activation and plasma membrane disintegration regulated by the subtilisin-like proprotein convertase furin D Schaale, Z Laspa, A Balmes, M Sigle, V Dicenta-Baunach, R Hochuli, X Fu, K Serafimov, T Castor, T Barm, KAL Müller, AK Rohlfing, S **Laufer**, TE Schäffer, M Lämmerhofer, M Gawaz The FASEB Journal 38 (21), e70155	2024	
668	A Defined Diet Combined with Sonicated Inoculum Provides a High Incidence, Moderate Severity Form of Experimental Autoimmune Encephalomyelitis (EAE)	2024	

	M Martorelli, M Dengler, J Laux, T Fischer, A Vaiceliunaite, U Hahn, T Weinstein, S Cruces, C Pokoj, L de Oliveira da Cunha, L Wohlbold, P Koch, S **Laufer**, M Burnet, F Maier ACS Pharmacology & Translational Science 7 (12), 3827-3845		
667	Wound healing potential and anti-inflammatory action of extracts and compounds of *Myrciaria plinioides* D. Legrand leaves DJ Marmitt, G Vettorazzi, L Bortoluzzi, C Alves, J Silva, S Pinteus, A Martins, H Gaspar, R Pedrosa, J da Silva, JA Pêgas Henriques, S **Laufer**, MI Goettert Inflammopharmacology 32 (5), 3327-3345	2024	
666	Sensors for Antibiotics Susceptibility Testing—Recent Advances O Riester, S **Laufer**, R Mertelsmann, HP Deigner Advanced Sensor Research 3 (10), 2400046	2024	
665	The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer CFF Gardani, FM Diz, LB Dondé, L Rockenbach, **S Laufer**, FB Morrone Frontiers in Immunology 15, 1455469	2024	
664	Das molekulare Interaktionsmuster von Lenvatinib ermöglicht die Inhibierung von Cholangiokarzinomen mit wildtype und rezeptormutierten FGFR2-Fusionen S Spahn, F Kleinhenz, E Shevchenko, A Stahl, Y Rasen, C Geisler, K Ruhm, M Klaumuenzer, T Kronenberger, **S Laufer**, H Sundberg-Malek, KC Buie, M Holger, S Biskup, K Schulze-Osthoff, M Templin, N Malek, M Bitzer Zeitschrift für Gastroenterologie 62 (09), KV 261	2024	
663	An Investigation of the Drug Release Kinetics of 3D-Printed Two Compartment Theophylline and Prednisolone Tablets T Pflieger, R Venkatesh, M Dachtler, **S Laufer**, DJ Lunter Available at SSRN 4932428	2024	
662	30 Years of Kinase Inhibitors: A Historical Overview and some Brazilian Contributions JGB Pedreira, **S Laufer** Journal of the Brazilian Chemical Society 35 (10), e-20240107	2024	
661	Wound healing potential and anti-inflammatory action of extracts and compounds of *Myrciaria plinioides* D. Legrand leaves DJ Marmitt, G Vettorazzi, L Bortoluzzi, C Alves, J Silva, S Pinteus, A Martins, H Gaspar, R Pedrosa, J da Silva, JAP Henriques, **S Laufer**, MI Goettert Inflammopharmacology, 1-19	2024	
660	Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy	2024	

	A Bayrak, M Szpakowska, V Dicenta-Baunach, M Counson, A Rasch, AK Rohlfing, A Chevigné, M Gawaz, **SA Laufer**, T Pillaiyar Journal of Medicinal Chemistry 67 (16), 14553-14573		
659	3.2. 2 Synthesis of a biocompatible benzophenone-substituted chitosan hydrogel as novel coating for PEEK with extraordinary strong antibacterial and anti-biofilm properties M Borgolte, O Riester, I Quint, F Blendinger, V Bucher, **S Laufer**, R Csuk A Multifaceted Approach to Preserve Effective Antibiotics Utilizing … ?????	2024	
658	Supporting Information Synthesis of a biocompatible benzophenone-substituted chitosan hydrogel as novel coating for PEEK with extraordinary strong antibacterial and anti … M Borgolte, O Riester, I Quint, F Blendinger, V Bucher, **S Laufer**, R Csuk, L Scotti, HP Deigner A Multifaceted Approach to Preserve Effective Antibiotics Utilizing … ?????	2024	
657	A. 1.2 Supporting Material: Rapid Phenotypic Antibiotics Susceptibility Analysis by a 3D Printed Prototype O Riester, L Kaiser, **S Laufer**, HP Deigner A Multifaceted Approach to Preserve Effective Antibiotics Utilizing … ??????	2024	
656	Influence of design parameters on sustained drug release properties of 3D-printed theophylline tablets T Pflieger, R Venkatesh, M Dachtler, K Cooke, **S Laufer**, D Lunter International Journal of Pharmaceutics 658, 124207	2024	
655	Targeting Lewy body dementia with neflamapimod-rasagiline hybrids C Albertini, S Petralla, F Massenzio, B Monti, N Rizzardi, C Bergamini, E Uliassi, F Borges, D Chavarria, G Fricker, M Goettert, T Kronenberger, M Gehringer, **S Laufer**, ML Bolognesi Archiv der Pharmazie 357 (6), 2300525	2024	
654	Hemin-induced platelet activation is regulated via ACKR3 chemokine surface receptor-implications for passivation of vulnerable atherosclerotic plaque Z Laspa, V Dicenta-Baunach, D Schaale, M Sigle, R Hochuli, T Castor, A Bayrak, T Harm, KAL Mueller, T Pillaiyar, **S Laufer**, AK Rohlfing, MP Gawaz bioRxiv, 2024.05. 13.593847	2024	
653	Towards a zero-waste sustainable biorefinery of Codium sp. seaweed: From bioactives application to soil enhancement materials A Martins, J Silva, C Alves, S Pinteus, C Félix, A Augusto, R Pedrosa, AS Mestre, RMM Santos, AP Carvalho, M Goettert, **S Laufer,** MFL Lemos Journal of Cleaner Production 453, 142191	2024	

652	Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death B Praefke, P Klövekorn, R Selig, W Albrecht, **S Laufer** US Patent App. 18/388,084	2024	
651	Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S_NAr Electrophiles M Schwarz, M Kurkunov, F Wittlinger, R Rudalska, G Wang, MP Schwalm, A Rasch, B Wagner, **SA Laufer**, S Knapp, D Dauch, M Gehringer Journal of medicinal chemistry 67 (8), 6549-6569	2024	
650	Protein-protein interaction modulators of aurora kinase a and their use in the prevention and/or treatment of cancer JJ Reiner, T Pantsar, D Flötgen, **S Laufer,** L Zender, M Henning US Patent App. 18/035,671	2024	
649	First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure S Zwirner, AAA Rmilah, S Klotz, B Pfaffenroth, P Kloevekorn, AA Moschopoulou, S Schuette, M Haag, R Selig, K Li, W Zhou, E Nelson, A Poso, H Chen, B Amiot, Y Jia, A Minshew, G Michalak, W Cui, E Rist, T Longerich, B Jung, P Felgendreff, O Trompak, PK Premsrirut, K Gries, TE Muerdter, G Heinkele, T Wuestefeld, D Shapiro, M Weissbach, A Koenigsrainer, B Sipos, AB Eiso, MO Zacarias, S Theisgen, N Gruenheit, S Biskup, M Schwab, W Albrecht, **S Laufer**, S Nyberg, L Zender Cell 187 (7), 1666-1684. e26	2024	
648	Rapid Phenotypic Antibiotics Susceptibility Analysis by a 3D Printed Prototype O Riester, L Kaiser, **S Laufer**, HP Deigner Advanced Science, 2308806	2024	
647	Development and characterization of kinase sparing TPX2-tethering Aurora kinase A ligands for cancer therapy AA Moschopoulou, M Henning, B Wagner, D Flötgen, J Reiner, Y Skliarenko, S Zwirner, C Hinterleitner, M Seehawer, L dArtista, E Rist, T Pantsar, T Kronenberger, D Dauch, C Gehring-Khav, A Poso, L Andreeva, M Schwab, M Forster, W Albrecht, **S Laufer**, L Zender Cancer Research 84 (6_Supplement), 4478-4478	2024	
646	Correction to “Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity” P Flury, J Breidenbach, N Krüger, R Voget, L Schäkel, Y Si, V Krasniqi, S Calistri, M Olfert, K Sylvester, C Rocha, R Ditzinger, A Rasch, S Pöhlmann, T Kronenberger, A Poso, K Rox, **SA Laufer**, CE Müller, M Gütschow, T Pillaiyar ACS Pharmacology & Translational Science 7 (4), 1195-1196	2024	

645	Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in *KRAS*-mutant cancers RA Jansen, S Mainardi, MH Dias, A Bosma, E van Dijk, R Selig, W Albrecht, **SA Laufer**, L Zender, R Bernards Proceedings of the National Academy of Sciences 121 (9), e2319492121	2024	
644	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death W Albrecht, **S Laufer**, R Selig, P Klövekorn, B Präfke US Patent 11,912,701	2024	
643	Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors F Wittlinger, BC Ogboo, E Shevchenko, T Damghani, CD Pham, IK Schaeffner, BT Oligny, SP Chitnis, TS Beyett, A Rasch, B Buckley, DA Urul, T Shaurova, EW May, EM Schaefer, MJ Eck, PA Hershberger, A Poso, **SA Laufer**, DE Heppner Communications Chemistry 7 (1), 38	2024	
642	*Journal of Medicinal Chemistry* Collection: Drug Discovery in Germany **S Laufer**, M Gehringer, A Titz Journal of Medicinal Chemistry 67 (4), 2237-2237	2024	
641	Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity P Flury, J Breidenbach, N Krüger, R Voget, L Schäkel, Y Si, V Krasniqi, S Calistri, M Olfert, K Sylvester, C Rocha, R Ditzinger, A Rasch, S Pöhlmann, T Kronenberger, A Poso, K Rox, **SA Laufer**, CE Müller, M Gütschow, T Pillaiyar ACS Pharmacology & Translational Science 7 (2), 493-514	2024	
640	HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents KB Waitman, LC de Almeida, MC Primi, JAEG Carlos, C Ruiz, T Kronenberger, **S Laufer**, MI Goettert, A Poso, SV Vassiliades, VAM de Souza, MFZJ Toledo, NMA Hassimotto, MD Cameron, TD Bannister, LV Costa-Lotufo, JA Machado-Neto, MT Tavares, R Parise-Filho European Journal of Medicinal Chemistry 263, 115935	2024	
639	Development of Highly Potent and Selective FGFR4 Inhibitors Based on SNAr Electrophiles M Schwarz, M Kurkunov, F Wittlinger, R Rudalska, G Wang, MP Schwalm, A Rasch, B Wagner, **SA Laufer**, S Knapp, D Dauch, M Gehringer ?????	2024	
638	Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death B Praefke, P Klövekorn, R Selig, W Albrecht, **S Laufer**	2024	

	US Patent 11,858,927		
637	Sensors for Antibiotics Susceptibility Testing—Recent Advances O Riester, **S Laufer**, R Mertelsmann, HP Deigner Advanced Sensor Research, 2400046	2024	
636	ACKR3 agonism induces heterodimerization with chemokine receptor CXCR4 and attenuates platelet function V Dicenta-Baunach, Z Laspa, D Schaale, M Sigle, A Bayrak, T Castor T Pillaiyar, **S Laufer**, MP Gawaz, AK Rohlfing bioRxiv, 2024.05. 10.593491	2024	
635	Toward more sustainable enzyme reactions: enhancing kinetics by polydimethylacrylamide implementation S Rentschler, M Borgolte, R Csuk, **S Laufer**, HP Deigner Green Chemistry 26 (3), 1653-1659	2024	
634	Development of Ligands for the Super Conserved Orphan G Protein-Coupled Receptor GPR27 with Improved Efficacy and Potency T Pillaiyar, M Wozniak, D Abboud, A Rasch, AD Liebing, A Poso, T Kronenberger, C Stäubert, **SA Laufer**, J Hanson Journal of Medicinal Chemistry; DOI: 10.1021/acs.jmedchem.3c02030	2023	
633	Ready-to-use nanopore platform for label-free small molecule quantification: Ethanolamine as first example I Quint, J Simantzik, L Kaiser, **S Laufer**, D Smith, M Kohl, HP Deigner Nanomedicine: Nanotechnology, Biology and Medicine, 102724	2023	
632	HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents KB Waitman, LC de Almeida, MC Primi, JAEG Carlos, C Ruiz, T Kronenberger, **S Laufer**, MI Goettert, A Poso, SV Vassiliades, VAM de Souza, MFZJ Toledo, NMA Hassimotto, MD Cameron, TD Bannister, LV Costa-Lotufo, JA Machado-Neto, MT Tavares, RParise-Filho European Journal of Medicinal Chemistry, DOI: 10.1016/j.ejmech.2023.115935	2023	
631	Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity P Flury, J Breidenbach, N Krüger, R Voget, LSchäkel, Y Si, V Krasniqi, S Calistri, M Olfert, K Sylvester, C Rocha, R Ditzinger, A Rasch, S Pöhlmann, T Kronenberger, A Poso, K Rox, **SA Laufer**, CE Müller, M Gütschow, T Pillaiyar ChemRxiv; DOI: 10.26434/chemrxiv-2023-ns203	2023	
630	Imidazo [4, 5-c] quinoline compounds and their use as atm kinase inhibitors **S Laufer**, M Forster, T Dimitrov, L Zender, A Moschopoulou	2023	

	US Patent App. 18/141,656		
629	The origin of potency and mutant-selective inhibition by bivalent ATP-allosteric EGFR inhibitors F Wittlinger, SP Chitnis, CD Pham, T Damghani, IK Schaeffner, MQ Deng, BC Ogboo, A Rasch, TS Beyett, B Buckley, F Feru, T Shaurova, C Knappe, MJ Eck, PA Hershberger, DA Scott, **SA Laufer**, DE Heppner ChemRxiv; DOI: 10.26434/chemrxiv-2023-zzfc3	2023	
628	Inherent Fluorescence Demonstrates Immunotropic Properties for Novel Janus Kinase 3 Inhibitors J Laux, M Martorelli, S Strass, D Schollmeyer, F Maier, M Burnet, **SA Laufer** ACS Pharmacology & Translational Science 2023, 6, 10, 1433-1452; doi.org/10.1021/acsptsci.3c00119	2023	
627	Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors F Wittlinger, BC Ogboo, E Shevchenko, T Damghani, CD Pham, IK Schaeffner, BT Oligny, SP Chitnis, TS Beyett, A Rasch, B Buckley, DA Urul, T Shaurova, EW May, EM Schaefer, MJ Eck, PA Hershberger, A Poso, **SA Laufer**, DE Heppner ChemRxiv; DOI: 10.26434/chemrxiv-2023-cs3xn-v2	2023	
626	Pitfalls and considerations in determining the potency and mutant selectivity of covalent epidermal growth factor receptor inhibitors KW Hoyt, DA Urul, BC Ogboo, F Wittlinger, **SA Laufer**, EM Schaefer, EW May, DE Heppner ChemRxiv; DOI: 10.26434/chemrxiv-2023-tkqqk	2023	
625	Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death M Juchum, R Selig, **S Laufer**, W Albrecht **US Patent** 11,731,968	2023	
624	Isolation and Identification of Phytocompounds from Maytenus dhofarensis and Their Biological Potentials F Al-Rubaiai, ZZ Al-Shariqi, KS Al-Shabibi, J Husband, AM Al-Hattali, M Goettert, **S Laufer**, Y Baqi, SI Hassan, MO Fatope Molecules 28 (16), 6077	2023	
623	Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo M Keppler, S Straß, S Geiger, T Fischer, N Späth, T Weinstein, A Schwamborn, J Guezguez, JH Guse, **S Laufer**, M Burnet Frontiers in Immunology 14, 1168252	2023	
622	Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2	2023	

	DB Anton, J Galvez Bulhões Pedreira, ML Zvirtes, **SA Laufer**, RG Ducati, M Goettert, LF Saraiva Macedo Timmers Journal of Chemical Information and Modeling; doi.org/10.1021/acs.jcim.3c00324		
621	Luteolin-7-O-Glucoside 对 6-OHDA 诱导的未分化和 RA 分化 SH-SY5Y 细胞损伤的神经保护作用 LF Hoffmann, A Martins, F Majolo, V Contini, **S Laufer**, MI Goettert **中国神**经再生研究 (**英文版**) 18 (6), 1265	2023	
620	A patent review of MAPK inhibitors (2018–present) VR Wydra, RB Ditzinger, NJ Seidler, FW Hacker, **SA Laufer** Expert Opinion on Therapeutic Patents 33 (6), 421-444	2023	
619	Immune cell targeted fumaric esters support a role of GPR109A as a primary target of monomethyl fumarate in vivo S Straß, J Geiger, N Cloos, N Späth, S Geiger, A Schwamborn, L De Oliveira da Cunha, M Martorelli, JH Guse, T Lucas Sandri, M Burnet, **S Laufer** Inflammopharmacology 31 (3), 1223-1239	2023	
618	Neural regeneration research model to be explored: SH-SY5Y human neuroblastoma cells LF Hoffmann, A Martins, F Majolo, V Contini, **S Laufer**, MI Goettert Neural Regeneration Research 18 (6), 1265-1266	2023	
617	Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-b]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities T Dimitrov, AA Moschopoulou, L Seidel, T Kronenberger, M Kudolo, A Poso, C Geibel, P Wölffing, D Dauch, L Zender, D Schollmeyer, J Bajorath, M Forster, **S Laufer** Journal of Medicinal Chemistry; doi.org/10.1021/acs.jmedchem.2c02104	2023	
616	Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio J Laux, M Martorelli, N Späth, F Maier, M Burnet, **SA Laufer** ACS Pharmacology & Translational Science; doi.org/10.1021/acsptsci.3c00043	2023	
615	The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation J Quancard, A Vulpetti, A Bach, B Cox, SM Guéret, IV Hartung, HF Koolman, **S Laufer**, J Messinger, G Sbardella, R Craft ChemMedChem 18 (9), e202300002	2023	

614	MKK4 Inhibitors—Recent Development Status and Therapeutic Potential L Katzengruber, P Sander, **S Laufer** International Journal of Molecular Sciences 24 (8), 7495	2023	
613	COVID-19 therapeutics: small-molecule drug development targeting SARS-CoV-2 main protease T Kronenberger, **SA Laufer**, T Pillaiyar Drug Discovery Today, 103579	2023	
612	Isostearic acid is an active component of imiquimod formulations used to induce psoriaform disease models S Straß, J Geiger, M Martorelli, S Geiger, N Cloos, M Keppler, T Fischer, L Riexinger, A Schwamborn, J Guezguez, N Späth, S Cruces, JH Guse, T Lucas Sandri, M Burnet, **S Laufer** Inflammopharmacology 31 (2), 799-812	2023	
611	3-benzoyl-1h-pyrrolo [2, 3-b] pyridine derivatives as mkk4 inhibitors for treating liver diseases R Selig, S Laufer, W Albrecht US Patent App. 17/792,685	2023	
610	Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors. T Damghani, F Wittlinger, TS Beyett, MJ Eck, **SA Laufer**, DE Heppner Methods Enzymology 2023:685:171-198.	2023	
609	Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design. F Wittlinger, BC Ogboo, CD Pham, IK Schaeffner, SP Chitnis, T Damghani, TS Beyett, A Rasch, B Buckley, DA Urul, T Shaurova, EW May, EM Schaefer, MJ Eck, PA Hershberger, SA Laufer, DE Heppner ChemRxiv 2023. DOI: 10.26434(chemrxiv-2023-cs3xn-v2	2023	
608	Discovery of Polyphenolic Natural Products as SARS-CoV-2 M^{pro} Inhibitors for COVID-19 N Krüger, T Kronenberger, H Xie, C Rocha, S Pöhlmann, H Su, Y Xu, **SA Laufer**, T Pillaiyar Pharmaceuticals 16 (2), 190	2023	
607	Centrally active p38alpha inhibiting compounds **S Laufer**, W Albrecht, P Koch, N Walter US Patent App. 17/638,751	2023	
606	Ready-to-use nanopore platform for ethanolamine quantification using an aptamer-based strand displacement assay. I Quint, J Simantzik, L Kaiser, **S Laufer**, R Csuk, D Smith, M Kohl, HP Deigner bioRxiv, 2023.02. 27.530168	2023	

605	Pharmacy Archives A Link, **S Laufer**, W Diederich, C Veale, A Artese, K Augustyns, ... ARCHIV DER PHARMAZIE 356 (1)	2023	
604	Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands DP Zlotos, T Kronenberger, **SA Laufer** Pharmaceutics 15 (1), 67	2023	
603	Antiulcerogenic Potential of the Ethanolic Extract of *Ceiba speciosa* (A. St.-Hil.) Ravenna Evaluated by In Vitro and In Vivo Studies JA Dörr, F Majolo, L Bortoluzzi, EZ de Vargas, J Silva, M Pasini, SN Stoll, R Lopes da Rosa, M Moreira Figueira, M Fronza, WO Beys-da-Silva, A Martins, H Gaspar, RP Pedrosa, **S Laufer**, MI Goettert International Journal of Molecular Sciences 23 (24), 15634	2022	
602	Direct 3D printed biocompatible microfluidics: assessment of human mesenchymal stem cell differentiation and cytotoxic drug screening in a dynamic culture system O Riester, **S Laufer,** HP Deigner Journal of Nanobiotechnology 20 (1), 1-18	2022	
601	Synthesis of a biocompatible benzophenone-substituted chitosan hydrogel as novel coating for PEEK with extraordinary strong antibacterial and anti-biofilm properties M Borgolte, O Riester, I Quint, F Blendinger, V Bucher, **S Laufer**, R Csuk, L Scotti, H-P Deigner Materials Today Chemistry 26, 101176	2022	
600	Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448) DE Heppner, F Wittlinger, TS Beyett, T Shaurova, DA Urul, B Buckley, CD Pham, IK Schaeffner, B Yang, BC Ogboo, EW May, EM Schaefer, MJ Eck, **SA Laufer**, PA Hershberger ACS Medicinal Chemistry Letters 13 (12), 1856-1863	2022	
599	Novel Approach to Pharmaceutical 3D-Printing Omitting the Need for Filament—Investigation of Materials, Process, and Product Characteristics T Pflieger, R Venkatesh, M Dachtler, K Eggenreich, **S Laufer**, D Lunter Pharmaceutics 14 (11), 2488	2022	
598	Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death B Pfaffenrot, R Selig, **S Laufer**, W Albrecht US Patent App. 17/630,105	2022	

597	Synergy of R-(–) carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation O Riester, P Burkhardtsmaier, Y Gurung, **S Laufer**, HP Deigner, MS Schmidt Scientific Reports 12 (1), 18019	2022	
596	Influence of diet and MOG35-55 peptide preparation on severity, survival, incidence and body weight in murine experimental autoimmune encephalomyelitis M Martorelli, J Laux, M Dengler, T Fischer, D Canjuga, A Vaiceliunaite, F Maier, M Burnet, **S Laufer** MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 221-221	2022	
595	Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation A Bayrak, F Mohr, K Kolb, M Szpakowska, E Shevchenko, V Dicenta, A-K Rohlfing, M Kudolo, T Pantsar, M Günther, AA Kaczor, A Poso, A Chevigné, T Pillaiyar, M Gawaz, **SA Laufer** Journal of Medicinal Chemistry 65 (19), 13365-13384	2022	
594	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death W Albrecht, S Laufer, R Selig, P Klövekorn, B Präfke US Patent App. 17/260,519	2022	
593	Pivotal blinded randomized trial of a novel pro-regenerative drug in post-resection liver failure A Abu Rmilah, K Li, E Larson, S Ellias, S Klotz, B Pfaffenroth, P Kloevekorn, R Selig, W Zhou, E Nelson, A Poso, H Chen, B Amiot, A Minshew, G Michalak, W Cui, W Albrecht, B Jung, O Trompak, S Zwirner, M Lutz, T Wuestefeld, **S Laufer**, L Zender, S Nyberg Transplantation 106 (8 S), 19-20	2022	
592	Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors M Juchum, B Pfaffenrot, P Klövekorn, R Selig, W Albrecht, L Zender, **SA Laufer** European Journal of Medicinal Chemistry 240, 114584	2022	
591	Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells J Laux, M Forster, L Riexinger, A Schwamborn, J Guezguez, C Pokoj, M Kudolo, LM Berger, S Knapp, D Schollmeyer, J Guse, M Burnet, **SA Laufer** ACS Pharmacology & Translational Science ?????	2022	
590	Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor	2022	

	B Jung, M Weissbach, M Lutz, R Selig, **S Laufer**, L Zender, M Feigh, M Berse, J Penski, E Kosmella, W Albrecht Journal of Hepatology 77, S737-S738		
589	Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination T Pillaiyar, P Flury, N Krüger, H Su, L Schäkel, E Barbosa Da Silva, O Eppler, T Kronenberger, T Nie, S Luedtke, C Rocha, K Sylvester, MRI Petry, JH McKerrow, A Poso, S Pöhlmann, M Gütschow, AJ O'Donoghue, Y Xu, CE Müller, **SA Laufer** Journal of Medicinal Chemistry 65 (13), 9376-9395	2022	
588	Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts A Bayrak, J Hanson, **S Laufer**, T Pillaiyar Future Medicinal Chemistry 14 (12), 899-913	2022	
587	Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─ What Is Expected? ("It is pretty easy to make a bad kinase inhibitor") **S Laufer**, J Bajorath, M Gehringer, N Gray, S Frye, CW Lindsley Journal of Medicinal Chemistry 65 (10), 6973 - 6974	2022	
586	Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity T Dimitrov, C Anli, AA Moschopoulou, T Kronenberger, M Kudolo, C Geibel, MP Schwalm, L Zender, M Forster, **S Laufer** European Journal of Medicinal Chemistry 235, 114234	2022	
585	2, 2, 2-Trifluoroethanol-mediated hydroarylation of fluorinated alkynes with indoles: Application to diindolylmethanes P Flury, O Eppler, D Schollmeyer, **S Laufer**, T Pillaiyar Archiv der Pharmazie, e2100488	2022	
584	Target Hopping from Protein Kinases to PXR: Identification of Small-Molecule Protein Kinase Inhibitors as Selective Modulators of Pregnane X Receptor from TüKIC Library EK Mustonen, T Pantsar, A Rashidian, J Reiner, M Schwab, **S Laufer**, O Burk Cells 11 (8), 1299	2022	
583	ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury AK Rohlfing, K Kolb, M Sigle, M Ziegler, A Bild, P Münzer, J Sudmann, V Dicenta, T Harm, MC Manke, S Geue, M Kremser, M Chatterjee, C Liang, H von Eysmondt, T Dandekar, D Heinzmann, M Günter, S von Ungern-Sternberg, M Büttcher, T Castor, S Mencl, F Langhauser,K Sies, D Ashour, MC Beker, M Lämmerhofer, SE	2022	

	Autenrieth, TE Schäffer, **S Laufer**, P Szklanna, P Maguire, M Heikenwalder, KAL Müller, DM Hermann, E Kilic, R Stumm, G Ramos, C Kleinschnitz, O Borste, HF Langer, D Rath, M Gawaz Nature Communications 13 (1), 1-20		
582	In vitro and in vivo anti-inflammatory and anticoagulant activities of Myrciaria plinioides D. Legrand ethanol leaf extract DJ Marmitt, S Bitencourt, CO Coura, M Berger, D Faleiro, DM Kich, B Caye, SM Immich, A Fernandes Frota, WO Beys-da-Silva, J Almeida Guimaraes, NM Barros Benevides, **S Laufer**, MI Goettert Inflammopharmacology 30 (2), 565-577	2022	
581	Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer CM Abdelmalek, Z Hu, T Kronenberger, J Küblbeck, FJM Kinnen, SS Hesse, A Malik, M Kudolo, R Niess, M Gehringer, L Zender, PA Witt-Enderby, DP Zlotos, **SA Laufer** Journal of Medicinal Chemistry 65 (6), 4616-4632	2022	
580	Neuroprotective Effect of Luteolin-7-O-Glucoside against 6-OHDA-Induced Damage in Undifferentiated and RA-Differentiated SH-SY5Y Cells SCH Rehfeldt, J Silva, C Alves, S Pinteus, R Pedrosa, **S Laufer**, MI Goettert International Journal of Molecular Sciences 23 (6), 2914	2022	
579	Development of the first covalent monopolar spindle kinase 1 (MPS1/TTK) Inhibitor RA M. Serafim, A da Silva Santiago, MP Schwalm, Z Hu, CV Dos Reis, JE Takarada, P Mezzomo, KB Massirer, M Kudolo, S Gerstenecker, A Chaikuad, L Zender, S Knapp, **S Laufer**, RM Counago, M Gehringer Journal of Medicinal Chemistry 65 (4), 3173-3192	2022	
578	Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors T Pantsar, PD Kaiser, M Kudolo, M Forster, U Rothbauer, **SA Laufer** Nature Communications 13 (1), 1-14	2022	
577	The functional role of p38 MAPK pathway in malignant brain tumors N Grave, TB Scheffel, FF Cruz, L Rockenbach, MI Goettert, S Laufer, ... Frontiers in Pharmacology 13	2022	
576	Discrepancy in interactions and conformational dynamics of pregnane X receptor (PXR) bound to an agonist and a novel competitive antagonist A Rashidian, EK Mustonen, T Kronenberger, M Schwab, O Burk, **SA Laufer**, T Pantsar Computational and Structural Biotechnology Journal 20, 3004-3018	2022	

575	New Horizons in Drug Discovery-Understanding and Advancing Different Types of Kinase Inhibitors: Seven Years in Kinase Inhibitor Research with Impressive Achievements and New Future Prospects **S Laufer**, J Bajorath Journal of Medicinal Chemistry 65 (2), 891-892	2021	
574	High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation C Carrillo García, C Becker, M Forster, S Lohmann, P Freitag, **S Laufer**, S Sievers, BK Fleischmann, M Hesse, D Schade Journal of Medicinal Chemistry 65 (2), 1505-1524	2021	
573	Design of a "two-in-one" mutant-selective epidermal growth factor receptor inhibitor that spans the orthosteric and allosteric sites F Wittlinger, DE Heppner, C To, M Günther, BH Shin, JK Rana, AM Schmoker, TS Beyett, LM Berger, BT Berger, N Bauer, JD Vasta, CR Corona, MB Robers, S Knapp, PA Janne, MJ Eck, **SA Laufer** Journal of Medicinal Chemistry 65 (2), 1370-1383	2021	
572	Biosynthesis of iron oxide magnetic nanoparticles using clinically isolated Pseudomonas aeruginosa AA Khan, S Khan, S Khan, S Rentschler, **S Laufer**, HP Deigner Scientific Reports 11 (1), 1-10	2021	
571	Dataset (X) related to publication: Decisive Role of Water and Protein Dynamics in Residence Time of p38a MAP Kinase Inhibitors T Pantsar, **S Laufer**	2021	
570	Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2) S Gerstenecker, L Haarer, M Schröder, M Kudolo, MP Schwalm, V Wydra, RAM Serafim, A Chaikuad, S Knapp, **S Laufer**, M Gehringer Cancers 13 (20), 5133	2021	
569	Methacryloyl-GlcNAc Derivatives Copolymerized with Dimethacrylamide as a Novel Antibacterial and Biocompatible Coating M Borgolte, O Riester, T Kacerova, S Rentschler, MS Schmidt, S Jacksch, M Egert, **S Laufer**, R Csuk, HP Deigner Pharmaceutics 13 (10), 1647	2021	
568	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer F Wittlinger, **SA Laufer** Expert Opinion on Drug Discovery 16 (10), 1091-1103	2021	
567	1st IN CLASS SMALL MOLECULE INHIBITORS OF MKK4 EXERT PRONOUNCED THERAPEUTIC EFFICACY IN RODENT	2021	

	AND NON-RODENT MODELS OF ACUTE AND CHRONIC LIVER FAILURE S Klotz, A Abu Rmilah, B Pfaffenrot, P Kloevekorn, R Selig, K Li, W Zhou, E Nelson, A Poso, H Chen, B Amiot, Y Jia, A Minshew, G Michalak, W Cui, W Albrecht, J Birgit, O Trompak, S Zwirner, M Lutz, T Wuestefeld, **S Laufer**, SL Nyberg, L Zender HEPATOLOGY 74, 157A-157A		
566	Neuropsychiatric Disorders and COVID-19: What We Know So Far F Majolo, GL Silva, L Vieira, C Anli, LFSM Timmers, **S Laufer**, MI Goettert Pharmaceuticals 14 (9), 933	2021	
565	Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe S Röhm, BT Berger, M Schröder, D Chatterjee, S Mathea, AC Joerger, DM Pinkas, JC Bufton, A Tjaden, L Kovooru, M Kudolo, C Pohl, AN Bullock, S Müller, **S Laufer**, S Knapp Journal of Medicinal Chemistry 64 (18), 13451-13474	2021	
564	Controlling the covalent reactivity of a kinase inhibitor with light M Reynders, A Chaikuad, BT Berger, K Bauer, P Koch, **S Laufer**, S Knapp, .D Trauner Angewandte Chemie International Edition 60 (37), 20178-20183	2021	
563	Chemical Probes for Understudied Kinases: Challenges and Opportunities RAM Serafim, JM Elkins, WJ Zuercher, **SA Laufer**, M Gehringer Journal of Medicinal Chemistry 65 (2), 1132-1170	2021	
562	Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death M Juchum, R Selig, S Laufer, W Albrecht US Patent App. 17/254,071	2021	
561	Improved Multigram Route to a Tricyclic Key Intermediate for Dibenzosuberone-Based p38 Inhibitors via an Optimized Early-Stage Heck Coupling M Forster, HK Wentsch-Teltschik, **SA Laufer** Organic Process Research & Development 25 (8), 1831-1840	2021	
560	Synthesis, Characterization, and in vivo Distribution of Intracellular Delivered Macrolide Short-Chain Fatty Acid Derivatives S Straß, A Schwamborn, M Keppler, N Cloos, J Guezguez, JH Guse, M Burnet, **S Laufer** ChemMedChem 16 (14), 2254-2269	2021	
559	Design, Synthesis and Biological Evaluation of Novel Pyrazolo [1, 2, 4] triazolopyrimidine Derivatives as Potential Anticancer Agents	2021	

	S Aliwaini, B Abu Thaher, I Al-Masri, N Shurrab, S El-Kurdi, D Schollmeyer, B Qeshta, M Ghunaim, R Csuk, S Laufer, L Kaiser, HP Deigner Molecules 26 (13), 4065		
558	Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors S Andreev, T Pantsar, R Tesch, N Kahlke, A El-Gokha, F Ansideri, L Grätz, J Romaco, G Sita, C Geibel, M Lämmerhofer, A Tarozzi, S Knapp, **SA Laufer**, P Koch Journal of Medicinal Chemistry 65 (2), 1283-1301	2021	
557	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death W Albrecht, **S Laufer**, R Selig, P Klövekorn, B Präfke US Patent 11,040,027	2021	
556	Simplifying Submission Requirements for the *Journal of Medicinal Chemistry* CW Lindsley, J Barrow, K Chibale, ML Bolognesi, S Conway, W Denny, K Ding, **S Laufer**, L Lai, H Liu, N Neamati, T Suzuki, N Meanwell, W Young Journal of Medicinal Chemistry 64 (12), 7877-7878	2021	
555	SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions LFSM Timmers, JV Peixoto, RG Ducati, JFR Bachega, L de Mattos Pereira, RA Caceres, F Majolo, G Liberato da Silva, D Bublitz Anton, OA Dallagostin, JA Pegas Henriques, LL Xavier, MI Goettert, **S Laufer** Scientific Reports 11 (1), 1-14	2021	
554	The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery J Quancard, A Bach, B Cox, R Craft, D Finsinger, SM Guéret, IV Hartung, **S Laufer**, J Messinger, G Sbardella, HF Koolman ChemMedChem 16 (11), 1737-1740	2021	
553	Design and synthesis of 1H-pyrazolo [3, 4-b] pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4)-A promising target for liver regeneration B Pfaffenrot, P Klövekorn, M Juchum, R Selig, W Albrecht, L Zender, **SA Laufer** European Journal of Medicinal Chemistry 218, 113371	2021	
552	Kinases as potential therapeutic targets for anti-coronaviral therapy T Pillaiyar, **S Laufer** Journal of Medicinal Chemistry 65 (2), 955-982	2021	

551	Current jakinibs for the treatment of rheumatoid arthritis: a systematic review CM Rocha, AM Alves, BF Bettanin, F Majolo, M Gehringer, **S Laufer**, MI Goettert Inflammopharmacology 29 (3), 595-615	2021	
550	Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors NM Tormählen, M Martorelli, A Kuhn, F Maier, J Guezguez, M Burnet, W Albrecht, **SA Laufer**, P Koch Journal of Medicinal Chemistry 65 (2), 1225-1242	2021	
549	Combining aptamers and antibodies: Lateral flow quantification for thrombin and interleukin-6 with smartphone readout M Mahmoud, C Ruppert, S Rentschler, **S Laufer**, HP Deigner Sensors and Actuators B: Chemical 333, 129246	2021	
548	A highly selective in vitro jnk3 inhibitor, fmu200, restores mitochondrial membrane potential and reduces oxidative stress and apoptosis in sh-sy5y cells SCH Rehfeldt, **S Laufer**, MI Goettert International Journal of Molecular Sciences 22 (7), 3701	2021	
547	A special view of what was almost forgotten: p38δ MAPK DB Anton, RG Ducati, LFSM Timmers, S Laufer, MI Goettert Cancers 13 (9), 2077	2021	
546	Synthesis, characterization and in vivo distribution of intracellular delivered macrolide SCFA derivatives. M Burnet, S Strass, A Schwamborn, M Keppler, J Guezguez, JH Guse, **S Laufer**, N Cloos ChemMedChem 16 (14), 2254-2269	2021	
545	Proteinkinase Inhibitors **S Laufer** (Editor) Topics in Medicinal Chemistry, Springer ISBN 978-3-030-68179-1	2021	
544	Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death B Praefke, P Klövekorn, R Selig, W Albrecht, **S Laufer** US Patent App. 16/965,912	2021	
543	Identification of novel pregnane X receptor antagonists in the Tubingen kinase inhibitor collection (TuKIC) compound library EK Mustonen, T Pantsar, A Rashidian, **S Laufer**, M Schwab, O Burk NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 394 (SUPPL 1), S43-S43	2021	

542	SARS-CoV-2 mutations in Brazil: from genomics to clinical conditions L Timmers, J Peixoto, R Ducati, JF Bachega, LM Pereira, RA Caceres, F Majolo, G Liberato Da Silva, D Bublitz Anton, MI Goettert, OA Dellagostin, J Henriques, L Xavier, **S Laufer** Scientific Reports 11	2021	
541	Review of trials currently testing stem cells for treatment of respiratory diseases: Facts known to date and possible applications to COVID-19 F Majolo, GL da Silva, L Vieira, LFSM Timmers, **S Laufer**, MI Goettert Stem Cell Reviews and Reports 17 (1), 44-55	2021	
540	LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer R Rudalska, J Harbig, MT Snaebjornsson, S Klotz, S Zwirner, L Taranets, F Heinzmann, T Kronenberger, M Forster, W Cui, L D'Artista, E Einig, M Hinterleitner, W Schmitz, A Dylawerska, TW Kang, A Poso, MT Rosenfeldt, NP Malek, M Bitzer, **S Laufer**, BJ Pichler, N Popov, A Schulze, L Zender, D Dauch Nature Cancer 2 (2), 201-217	2021	
539	*N*-(6-Chloro-3-nitropyridin-2-yl)-5-(1-methyl-1*H*-pyrazol-4-yl)isoquinolin-3-amine V Wydra, S Gerstenecker, D Schollmeyer, S Andreev, T Dimitrov, RAM Serafim, **S Laufer**, M Gehringer Molbank 2021 (1), M1181	2021	
538	From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4) P Kloevekorn, B Pfaffenrot, M Juchum, R Selig, W Albrecht, L Zender, **SA Laufer** European Journal of Medicinal Chemistry 210, 112963	2021	
537	Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4 T Kircher, T Pantsar, A Oder, JP von Kries, M Juchum, B Pfaffenrot, P Kloevekorn, W Albrecht, R Selig, **S Laufer** European Journal of Medicinal Chemistry 209, 112901	2021	
536	Molecular Design of a "Two-in-One" Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor F Wittlinger, DE Heppner, C To, M Guenther, BH Shin, JK Rana, AM Schmoker, TS Beyett, PA Jänne, MJ Eck, **S Laufer** Journal of Medicinal Chemistry 65 (2), 1370-1383	2021	
535	c-Jun N-terminal kinase inhibitors as potential leads for new therapeutics for Alzheimer's diseases SC Hepp Rehfeldt, F Majolo, MI Goettert, **S Laufer**	2020	

	International Journal of Molecular Sciences 21 (24), 9677		
534	The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: Validating Chemical Probes J Quancard, B Cox, D Finsinger, SM Guéret, IV Hartung, HF Koolman, J Messinger, G Sbardella, **S Laufer** ChemMedChem 15 (24), 2388-2390	2020	
533	Selective targeting of the αC and DFG-out pocket in p38 MAPK S Roehm, M Schröder, JE Dwyer, CS Widdowson, A Chaikuad, BT Berger, AC Joerger, A Krämer, J Harbig, D Dauch, M Kudolo, **S Laufer**, MC Bagley, S Knapp European Journal of Medicinal Chemistry 208, 112721	2020	
532	Discovery of a novel class of covalent dual inhibitors targeting the protein kinases BMX and BTK M Forster, XJ Liang, M Schröder, S Gerstenecker, A Chaikuad, S Knapp, **S Laufer**, M Gehringer International Journal of Molecular Sciences 21 (23), 9269	2020	
531	Duplex Shiny app quantification of the sepsis biomarkers C-reactive protein and interleukin-6 in a fast quantum dot labeled lateral flow assay C Ruppert, L Kaiser, LJ Jacob, **S Laufer**, M Kohl, HP Deigner Journal of Nanobiotechnology 18 (1), 1-11	2020	
530	Chemical Space Exploration of Oxetanes FRS Alves, RM Couñago, **S Laufer** International Journal of Molecular Sciences 21 (21), 8199	2020	
529	Discovery and Evaluation of Enantiopure 9*H*-pyrimido[4,5-*b*]indoles as Nanomolar GSK-3β Inhibitors with Improved Metabolic Stability S Andreev, T Pantsar, A El-Gokha, F Ansideri, M Kudolo, DB Anton, G Sita, J Romasco, C Geibel, M Lämmerhofer, MI Goettert, A Tarozzi**, SA Laufer,** P Koch International Journal of Molecular Sciences 21 (21), 7823	2020	
528	Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships O Laufkötter, **S Laufer**, J Bajorath European Journal of Medicinal Chemistry 204, 112641	2020	
527	Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome O Laufkötter, **S Laufer**, J Bajorath Data in Brief 32, 106189	2020	
526	New Horizons in Drug Discovery-Understanding and Advancing Kinase Inhibitors: Special Issue and Call for Papers **S Laufer**, K Briner, J Bajorath, GI Georg, S Wang	2020	

	Journal of Medicinal Chemistry 63 (15), 7921-7922		
525	Candidate drugs against SARS-CoV-2 and COVID-19 DL McKee, A Sternberg, U Stange, **S Laufer**, C Naujokat Pharmacological Research 157, 104859	2020	
524	An updated patent review of p38 MAP kinase inhibitors (2014-2019) V Haller, P Nahidino, M Forster, **SA Laufer** Expert Opinion on Therapeutic Patents 30 (6), 453-466	2020	
523	Neuroprotective potential of Myrciaria plinioides D. Legrand extract in an in vitro human neuroblastoma model DJ Marmitt, C Alves, J Silva, S Pinteus, T Schneider, RCV Santos, EM de Freitas, R Pedrosa, **S Laufer**, MI Goettert Inflammopharmacology 28 (3), 737-748	2020	
522	Dapsone is not a pharmacodynamic lead compound for its aryl derivatives T Scior, HH Abdallah, K Salvador-Atonal, **S Laufer** Current Computer-aided Drug Design 16 (3), 327-339	2020	
521	Bioisosteric Replacement of Arylamide-Linked Spine Residues with *N*-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I ½ p38α MAP Kinase Inhibitors JGB Pedreira, P Nahidino, M Kudolo, T Pantsar, BT Berger, M Forster, S Knapp, **S Laufer**, EJ Barreiro Journal of Medicinal Chemistry 63 (13), 7347-7354	2020	
520	Antimicrobial and antileukemic effects: in vitro activity of *Calyptranthes grandifolia* aqueous leaf extract F Majolo, S Bitencourt, B Wissmann Monteiro, G Viegas Haute, C Alves, J Silva, S Pinteus, RC Vianna Santos, HF Vieira Torquato, EJ Paredes-Gamero, JR Oliveira, CF Volken De Souza, RF Pinto Pedrosa, **S Laufer**, MI Goettert Journal of Toxicology and Environmental Health, Part A 83 (8), 289-301	2020	
519	Structural basis for EGFR mutant inhibition by trisubstituted imidazole inhibitors DE Heppner, M Günther, F Wittlinger, **SA Laufer**, MJ Eck Journal of Medicinal Chemistry 63 (8), 4293-4305	2020	
518	The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma L Oguh-Olayinka, V Agarwal, D Ranatunge, A Campbell, **S Laufer**, L Cawkwell, MJ Lind Pathology & Oncology Research 26 (2), 985-995	2020	

517	Mapping the S1 and S1'subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents L Cianni, C Lemke, E Gilberg, C Feldmann, F Rosini, FR Rocho, JFR Ribeiro, DY Tezuka, CD Lopes, S de Albuquerque, J Bajorath, **S Laufer**, A Leitao, M Gütschow, CA Montanari PLoS Neglected Tropical Diseases 14 (3), e0007755	2020	
516	Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors M González-Medina, F Miljković, GS Haase, P Drueckes, J Trappe, **S Laufer,** J Bajorath European Journal of Medicinal Chemistry 187, 112004	2020	
515	P139 EFFECT OF LYSOSOMAL SHORT CHAIN FATTY ACID DELIVERY ON IMMUNE RESPONSE S Strass, C Heinzel, N Cloos, M Keppler, J Guse, M Burnet, **S Laufer** Inflammatory Bowel Diseases 26 (Supplement_1), S12-S12	2020	
514	P139 EFFECT OF LYSOSOMAL SHORT CHAIN FATTY ACID DELIVERY ON IMMUNE RESPONSE S Strass, C Heinzel, N Cloos, M Keppler, J Guse, M Burnet, **S Laufer** Gastroenterology 158 (3), S20	2020	
513	Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 M Chen, C Neul, E Schaeffeler, F Frisch, S Winter, M Schwab, H Koepsell, S Hu, **S Laufer**, SD Baker, A Sparreboom, AT Nies Clinical Pharmacology & Therapeutics 107 (1), 227-237	2020	
512	*In vitro* activities of *Ceiba speciosa* (A.St.-Hil) Ravenna aqueous stem bark extract JA Dörr, S Bitencourt, L Bortoluzzi, C Alves, J Silva, S Stoll, S Pinteus, AA Boligon, RC Vianna Santos, **S Laufer**, R Pedrosa, MI Goettert Natural Product Research 33 (23), 3441-3444	2019	
511	Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis P Guenthoer, K Fuchs, G Reischl, L Quintanilla-Martinez, I Gonzalez-Menendez, **S Laufer**, BJ Pichler, M Kneiling Inflammopharmacology 27 (6), 1217-1227	2019	
510	Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation A Astolfi, M Kudolo, J Brea, G Manni, G Manfroni, D Palazzotti, S Sabatini, F Ceccetti, T Felicetti, R Cannalire, S Massari, O Tabarrini, MI Loza, F Fallarino, V Ceccetti, **SA Laufer**, ML Barreca European Journal of Medicinal Chemistry 182, 111624	2019	

509	Fast iterative synthetic approach toward identification of novel highly selective p38 MAP kinase inhibitors S Röhm, BT Berger, M Schröder, A Chaikuad, R Winkel, KFW Hekking, JJC Benningshof, G Müller, R Tesch, M Kudolo, M Forster, **S Laufer**, S Knapp Journal of Medicinal Chemistry 62 (23), 10757-10782	2019	
508	Visual aptamer-based capillary assay for ethanolamine using magnetic particles and strand displacement M Mahmoud, **S Laufer**, HP Deigner Microchimica Acta 186 (11), 1-8	2019	
507	Pyridinylimidazoles as GSK3β inhibitors: the impact of tautomerism on compound activity via water networks F Heider, T Pantsar, M Kudolo, F Ansideri, A De Simone, L Pruccoli, T Schneider, MI Goettert, A Tarozzi, V Andrisano, **SA Laufer**, P Koch ACS Medicinal Chemistry Letters 10 (10), 1407-1414	2019	
506	Targeting the r-spine: Design, synthesis, and biological evaluation of novel type I1/2 p38 alpha MAP kinase inhibitors with excellent selectivity, high potency, and prolonged target residence time. Implication for cancer- and CNS-applications **S Laufer**, H Wentsch, N Walter, M Laemmerhofer, R Buijsman, D Rauh, L Zender ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 258	2019	
505	Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors F Heider, F Ansideri, R Tesch, T Pantsar, U Haun, E Döring, M Kudolo, A Poso, W Albrecht, **SA Laufer**, P Koch European Journal of Medicinal Chemistry 175, 309-329	2019	
504	Natural chromones as potential anti-inflammatory agents: Pharmacological properties and related mechanisms LCF Opretzka, RF do Espírito-Santo, OA Nascimento, LS Abreu, IM Alves, E Döring, MB Pereira Soares, E da Silva Velozo, **SA Laufer**, CF Villarreal International Immunopharmacology 72, 31-39	2019	
503	Liver X receptor mediated lipotoxicity represents a treatment option for liver cancer R Rudalska, J Harbig, M Snaebjoernsson, L Taranets, F Heinzmann, S Zwirner, WC Hu, T Kronenberger, TW Kang, A Poso, **S Laufer**, M Rosenfeldt, NP Malek, B Pichler, N Popov, A Schulze, L Zender, D Dauch Cancer Research 79 (13_Supplement), 4377-4377	2019	
502	Myricetin inhibits panel of kinases implicated in tumorigenesis	2019	

	S Stoll, S Bitencourt, **S Laufer**, M Inês Goettert Basic & Clinical Pharmacology & Toxicology 125 (1), 3-7		
501	Design, Synthesis and Biological Evaluation of 7-Chloro-9*H*-pyrimido[4,5-*b*]indole-based Glycogen Synthase Kinase-3β Inhibitors S Andreev, T Pantsar, F Ansideri, M Kudolo, M Forster, D Schollmeyer, **SA Laufer**, P Koch Molecules 24 (12), 2331	2019	
500	Are peptides a solution for the treatment of hyperactivated JAK3 pathways? A Dullius, CM Rocha, **S Laufer**, CFV de Souza, MI Goettert Inflammopharmacology 27 (3), 433-452	2019	
499	Data for homogeneous thermofluorimetric assays for ethanolamine using aptamers and a PCR instrument M Mahmoud, **S Laufer**, HP Deigner Data in Brief 24, 103946	2019	
498	Adjunctive role of Calyptranthes tricona extract with probiotic Kluyveromyces marxianus on colorectal adenocarcinoma Caco-2 cells DM Kich, S Bitencourt, D Faleiro, SM Immich, DJ Marmitt, T Baldasso, G Viegas Haute, J Rodrigues de Oliveira, **S Laufer**, R Pedrosa, CF Volken de Souza, MI Goettert Phytochemistry Letters 30, 1-5	2019	
497	An aptamer based thermofluorimetric assay for ethanolamine M Mahmoud, **S Laufer**, HP Deigner Biochimie 158, 233-237	2019	
496	Selective targeting of JAK3 with new small molecular compounds J Holstein, M Forster, **S Laufer**, K Ghoreschi EXPERIMENTAL DERMATOLOGY 28 (3), E72-E72	2019	
495	N^1-{4-[2-(Methylthio)-1*H*-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine A El-Gokha, F Ansideri, S Andreev, D Schollmeyer, **S Laufer**, P Koch Molbank 2019 (1), M1048	2019	
494	Synthesis and structure-activity-relationship of 3, 4-Diaryl-1H-pyrrolo [2, 3-b] pyridines as irreversible Inhibitors of mutant EGFR-L858R/T790M M Günther, J Laux, **S Laufer** European Journal of Pharmaceutical Sciences 128, 91-96	2019	
493	JAK3 and p38 MAPK inhibitors regulates hepatocellular carcinoma proliferation M Goettert, T Schneider, **S Laufer**	2019	

	NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 392, S51-S51		
492	A smartphone readout system for gold nanoparticle-based lateral flow assays: Application to monitoring of digoxigenin C Ruppert, N Phogat, **S Laufer**, M Kohl, HP Deigner Microchimica Acta 186 (2), 1-9 Electronic Supplementary Material (ESM) on "A Smartphone readout…"	2019	
491	Sorafenib therapy for treatment of liver cancer is independent from organic cation transporter 1 (OCT1/SLC22A1) M Chen, C Neul, E Schaeffeler, F Frisch, S Winter, M Schwab, H Koepsell, S Hu, **S Laufer**, SD Baker, A Sparreboom, AT Nies NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 392, S17-S18	2019	
490	A novel scaffold for EGFR inhibition: introducing N-(3-(3-phenylureido) quinoxalin-6-yl) acrylamide derivatives DN do Amaral, J Lategahn, HH Fokoue, EMB da Silva, CMR Sant'Anna, D Rauh, EJ Barreiro, **S Laufer**, L Moreira Lim Scientific Reports 9 (1), 1-12 Supplementary Material on "A novel Scaffold for EGFR…"	2019	
489	Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions J Schwenck, A Maurer, B Fehrenbacher, R Mehling, P Knopf, N Mucha, D Haupt, K Fuchs, CM Grissinger, D Bukala, J Holstein, M Schaller, I Gozalez Menendez, K Ghoreschi, L Quintanilla-Martinez, M Gütschow, **S Laufer**, T Reinheckel, M Röcken, H Kalbacher, BJ Pichler, M Kneiling Theranostics 9 (13), 3903	2019	
488	Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology M Gehringer, **SA Laufer** Journal of Medicinal Chemistry 62 (12), 5673-5724	2018	
487	In vitro activities of Ceiba speciose (A.St.-Hil) Ravenna aqueous stem bark extract JA Dörr, S Bitencourt, L Bortoluzzi, C Alves, J Silva, SN Stoll, SF Goncalves Pinteus, A Augusti Boligon, RC Vianna Santos, **S Laufer**, R Pedrosa, MI Goettert Natural Product Research 33 (46): 1-4	2018	
486	Donated chemical probes for open science: Shown here are target and compound related criteria applied by the Structural Genomics Consortium. S. Müller, S Ackloo, CH Arrowsmith, M Bauser, JL Baryza, J Blagg, J Böttcher, C Bountra, PJ Brown, ME Bunnage, AJ Carter, D Damerell, V Dötsch, DH Drewry, AM Edwards, J Edwards, JM	2018	

	Elkins, C Fischer, SV Frye, A Gollner, C Grimshaw, A IJzerman, T Hanke, IV Hartung, S Hitchcock, T Howe, TV Hughes, **S Laufer**, V Li, S Liras, BD Marsden, H Matsui, J Mathias, RC O'Hagan, DR Owen, V Pande, D Rauh, SH Rosenberg, B Roth, N Schneider, C Scholten, KS Saikatendu, A Simeonov, M Takizawa, C Tse, PR Thompson, DK Treiber, AY Viana, CI Wells, TM Willson, WJ Zuercher, S Knapp, A Mueller-Fahrnow eLife Sciences 7		
485	Substituted benzamides from anti-inflammatory and p38 kinase inhibitors to antitubercular activity: design, synthesis and screening R Kulkarni, U Mitkari, G Achaiah, **S Laufer**, D Bikshapti, VM Chandrashekar, PB Gurav, SJ Joshi, VD Chipade Mini Reviews in Medicinal Chemistry 18 (17), 1486-1497	2018	
484	Kinase inhibitors P Koch, **S Laufer** Molecules 23 (7), 1818	2018	
483	Structural Optimization of a Pyridinylimidazole scaffold: shifting the selectivity from p38α mitogen-activated protein kinase to c-Jun N-terminal kinase 3 F Ansideri, JT Macedo, M Eitel, A El-Gokha, DS Zinad, C Scarpellini, M Kudolo, D Schollmeyer, FM Boeckler, BS Blaum, **SA Laufer**, P Koch ACS Omega 3 (7), 7809-7831	2018	
482	NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation M Blaess, N Bibak, RA Claus, M Kohl, GA Bonaterra, R Kinscherf, **S Laufer**, HP Deigner European Journal of Medicinal Chemistry 153, 73-104	2018	
481	Development, Optimization, and Structure–Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-*d*]pyrrolo[2,3-*b*]pyridine scaffold M Forster, A Chaikuad, T Dimitrov, E Döring, J Holstein, BT Berger, M Gehringer, K Ghoreschi, S Müller, S Knapp, **SA Laufer** Journal of Medicinal Chemistry 61 (12), 5350-5366	2018	
480	The cysteinome of protein kinases as a target in drug development A Chaikuad, P Koch, **SA Laufer**, S Knapp Angewandte Chemie International Edition 57 (16), 4372-4385	2018	
479	Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung A Chaikuad, P Koch, **SA Laufer**, S Knapp Angewandte Chemie 130 (16), 4456-4470	2018	

478	A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles as p38α Mitogen-Activated Protein Kinase Inhibitors F Ansideri, S Andreev, A Kuhn, W Albrecht, **SA Laufer**, P Koch Molecules 23 (1), 221	2018	
477	Donated chemical probes for open science S Müller, S Ackloo, CH Arrowsmith, M Bauser, JL Baryza, J Blagg, J Böttcher, C Bountra, PJ Brown, ME Bunnage, AJ Carter, D Damerell, V Dötsch, DH Drewry, AM Edwards, J Edwards, JM Elkins, C Fischer, SV Frye, A Gollner, CE Grimshaw, A IJzerman, T Hanke, IV Hartung, S Hitchcock, T Howe, TV Hughes **S Laufer**,VMJ Li, S Liras, BD Marsden, H Matsui, J Mathias, RC O'Hagan, DR Owen, V Pande, D Rauh, SH Rosenberg, BL Roth, NS Schneider, C Scholten, KS Saikatendu, A Simeonov, M Taikizawa, C Tse, PR Thompson, DK Treiber, AY Viana, CI Wells, TM Wilson, WJ Zuercher, S Knapp, A Müller-Fahrnow eLife 7	2018	
476	Abstract B167: KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736 p38 inhibitor V Vuaroqueaux, G Kelter, HR Hendriks, **S Laufer**, HH Fiebig Molecular Cancer Therapeutics 17 (1_Supplement), B167-B167	2018	
475	Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones S Herrmann, T Schübel, FN Costa, MLC Barbosa, FF Ferreira, TLMF Dias, MV Araujo, MS Alexandre-Moreira, LM Lima, **S Laufer**, EJ Barreiro Anais da Academia Brasileira de Ciências 90, 1073-1088	2018	
474	Neue Anwendungen der Klick-Chemie in Zellbiologie und Wirkstoffentwicklung M Gehringer, **SA Laufer** Angewandte Chemie 129 (49), 15709-15711	2017	
473	Click chemistry: Novel applications in cell biology and drug discovery M Gehringer, **SA Laufer** Angewandte Chemie International Edition 56 (49), 15504-15505	2017	
472	P38 Kinase, SGK1 and NF-κB Dependent Up-Regulation of Na+/Ca2+ Exchanger Expression and Activity Following TGFß1 Treatment of Megakaryocytes T Al-Maghout, L Pelzl, I Sahu, B Sukkar, Z Hosseinzadeh, R Gutti, **S Laufer**, J Voelkl, B Pieske, M Gawaz, F Lang Cellular Physiology and Biochemistry 42 (6), 2169-2181	2017	
471	From 2-alkylsulfanylimidazoles to 2-alkylimidazoles: an approach towards metabolically more stable p38α MAP kinase inhibitors	2017	

	F Heider, U Haun, E Döring, M Kudolo, C Sessler, W Albrecht, **S Laufer**, P Koch Molecules 22 (10), 1729		
470	Design, Synthesis, and Biological Evaluation of Novel Type I$^{1}/_{2}$ p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target … NM Walter, HK Wentsch, M Bührmann, SM Bauer, E Döring, S Mayer-Wrangowski, A Sievers-Engler, N Willemsen-Seegers, G Zaman, R Buijsman, M Lämmerhofer, D Rauh, **SA Laufer** Journal of medicinal chemistry 60 (19), 8027-8054	2017	
469	Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting M Forster, M Gehringer, **SA Laufer** Bioorganic & medicinal chemistry letters 27 (18), 4229-4237	2017	
468	EGFR triple mutant: Recent set-backs and new hopes in fighting mutant non-small cell lung cancer **S Laufer,** M Guenther, M Juchum, E Doering, M Keul, J Lategahn, H Tumbrink, J Engel, D Rauh ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 254	2017	
467	Progress towards a public chemogenomic set for protein kinases and a call for contributions DH Drewry, CI Wells, DM Andrews, R Angell, H Al-Ali, AD Axtman, SJ Capuzzi, JM Elkins, P Ettmayer, M Frederiksen, O Gileadi, N Gray, A Hooper, S Knapp, **S Laufer**, U Luecking, M Michaelides, S Müller, E Muratov, RA Denny, KS Saikatendu, DK Treiber, WJ Zuercher, TM Wilson PloS one 12 (8), e0181585	2017	
466	Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males S Pace, C Pergola, F Dehm, A Rossi, J Gerstmeier, F Troisi, H Pein, AM Schaible, C Weinigel, S Rummler, H Northoff, **S Laufer**, TJ Maier, O Radmark, B Samuelsson, A Koeberle, L Sautebin, O Werz The Journal of clinical investigation 127 (8), 3167-3176	2017	
465	Discovery of *N*-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3*H*-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with … W Albrecht, A Unger, SM Bauer, **SA Laufer** Journal of Medicinal Chemistry 60 (13), 5290-5305	2017	
464	Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate … M Gunther, J Lategahn, M Juchum, E Doring, M Keul, J Engel, HL Tumbrink, D Rauh, **S Laufer**	2017	

	Journal of medicinal chemistry 60 (13), 5613-5637		
463	Proteasome activation by small molecules Y Leestemaker, A de Jong, KF Witting, R Penning, K Schuurman, B Rodenko, EA Zaal, B van de Kooij, **S Laufer** AJR Heck, J Borst, W Scheper, CR Berkers, H Ovaa Cell chemical biology 24 (6), 725-736. e7	2017	
462	Trisubstituted imidazoles with a rigidized hinge binding motif act as single digit nM inhibitors of clinically relevant EGFR L858R/T790M and L858R/T790M/C797S mutants: an … M Juchum, M Günther, E Döring, A Sievers-Engler, M Lämmerhofer, **S Laufer** Journal of medicinal chemistry 60 (11), 4636-4656	2017	
461	Optimierte Bindungsdauer am Zielenzym: Typ-I-Inhibitoren der p38α-MAP-Kinase mit verbesserter Bindungskinetik durch direkte Interaktion mit der R-Spine HK Wentsch, NM Walter, M Bührmann, S Mayer-Wrangowski, D Rauh, GJR Zaman, N Willemsen-Seegers, RC Buijsman, M Henning, D Dauch, L Zender, **S Laufer** Angewandte Chemie 129 (19), 5448-5453	2017	
460	Optimized Target Residence Time: Type I Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine HK Wentsch, NM Walter, M Bührmann, S Mayer-Wrangowski, D Rauh, GJR Zaman, N Willemsen-Seegers, RC Buijsman, M Henning, D Dauch, L Zender, **S Laufer** Angewandte Chemie International Edition 56 (19), 5363-5367	2017	
459	In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of hypoxia-inducible factor and enhanced reactive oxygen species … K Fuchs, A Kuehn, M Mahling, P Guenthoer, A Hector, J Schwenck, D Hartl, **S Laufer**, U Kohlhofer, L Quintanilla-Martinez, G Reischl, M Röcken, BJ Pichler, M Kneiling Journal of Nuclear Medicine 58 (5), 853-860	2017	
458	In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of HIF and enhanced ROS generation K Fuchs, A Kuehn, M Mahling, P Guenthoer, A Hector, D Hartl, **S Laufer**, U Kohlhofer, L Quintanilla-Martinez, G Reischl, M Röcken, BJ Pichler, M Kneiling Journal of Nuclear Medicine	2017	
457	Tri-and tetrasubstituted pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3 F Muth, A El-Gokha, F Ansideri, M Eitel, E Döring, A Sievers-Engler, A Lange, FM Boeckler, M Lämmerhofer, P Koch, **SA Laufer**	2017	

	Journal of Medicinal Chemistry 60 (2), 594-607		
456	Are Two Better Than One in Rheumatoid Arthritis? Development of Dual p38α MAPK/PDE-4 Inhibitors for Treatment of TNFα-Driven Diseases W Albrecht, SM Bauer, **SA Laufer** Elsevier	2017	
455	Multi-gram Preparation of 7-Nitroquinoxalin-2-amine DN Amaral, FR Alves, EJ Barreiro, **SA Laufer,** LM Lima Journal of the Brazilian Chemical Society 28, 1874-1878	2017	
454	Neuromodulatory effects of Calyptranthes grandifolia extracts against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells DM Kich, S Bitencourt, C Alves, J Silva, S Pinteus, R Pedrosa, **S Laufer**, CF Volken de Souza, MI Goettert Biomedicine & Pharmacotherapy 84, 382-386	2016	
453	IL-1β, IL-18, and eicosanoids promote neutrophil recruitment to pore-induced intracellular traps following pyroptosis I Jorgensen, JP Lopez, **SA Laufer**, EA Miao European journal of immunology 46 (12), 2761-2766	2016	
452	Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket M Forster, A Chaikuad, SM Bauer, J Holstein, MB Robers, CR Corona, M Gehringer, E Pfaffenrot, K Ghoreschi, S Knapp, **SA Laufer** Cell chemical biology 23 (11), 1335-1340	2016	
451	Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors C Neul, E Schaeffeler, A Sparreboom, **S Laufer**, M Schwab, AT Nies Trends in pharmacological sciences 37 (11), 904-932	2016	
450	Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1) D Ostrovskyi, T Rumpf, J Eib, A Lumbroso, I Slynko, S Klaeger, S Heinzlmeir, M Forster, M Gehringer, E Pfaffenrot, SM Bauer, K Schmidtkunz, S Wenzler, E Metzger, B Kuster, S **Laufer**, R Schüle, W Sippl, B Breit, M Jung Future Medicinal Chemistry 8 (13), 1537-1551	2016	
449	Lungenkrebs: EGFR-Inhibitoren mit hoher Wirksamkeit gegen die therapieresistente L858R/T790M/C797S-Mutante. M Günther, M Juchum, G Kelter, H Fiebig, **S Laufer** Angewandte Chemie 128 (36), 11050-11054	2016	
448	Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant	2016	

	M Günther, M Juchum, G Kelter, H Fiebig, **S Laufer** Angewandte Chemie International Edition 55 (36), 10890-10894		
447	Why antidiabetic vanadium complexes are not in the pipeline of "big pharma" drug research? A critical review T Scior, J Antonio Guevara-Garcia, QT Do, P Bernard, **S Laufer** Current medicinal chemistry 23 (25), 2874-2891	2016	
446	Stimulating effect of sclareol on suicidal death of human erythrocytes E Signoretto, **SA Laufer,** F Lang Cellular Physiology and Biochemistry 39 (2), 554-564	2016	
445	Poly [[tetramethanolbis [4-oxo-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-4, 5-dihydro-1H-pyrazolo [3, 4-d] pyrimidin-6-olato] disodium]–diethyl ether–methanol (1/1/2)] B Abu Thaher, D Schollmeyer, **S Laufer** IUCrData 1 (7), x161081	2016	
444	A MYC-Aurka protein complex represents an actionable target in p53 altered liver cancer D Daniel, R Rudalska, G Cossa, JC Nault, S Imbeaud, NP Malek, T Longerich, **S Laufer**, A Poso, J Zucman-Rossi, M Eilers, L Zender Cancer Research 76 (14_Supplement), 1257-1257	2016	
443	Evaluation of organic cation transporter 1 (OCT1, SLC22A1) as transporter for sorafenib C Neul, SD Baker, A Sparreboom, E Schaeffeler, **S Laufer**, M Schwab, AT Nies Cancer Research 76 (14_Supplement), 257-257	2016	
442	Design and Development of Microsomal Prostaglandin E_2 Synthase-1 Inhibitors: Challenges and Future Directions A Koeberle, **SA Laufer**, O Werz Journal of medicinal chemistry 59 (13), 5970-5986	2016	
441	Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord S Taves, T Berta, DL Liu, S Gan, G Chen, YH Kim, T Van de Ven, **S Laufer**, RR Ji Brain, behavior, and immunity 55, 70-81	2016	
440	SCISSOR—Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol MA Kopp, T Liebscher, R Watzlawick, P Martus, **S Laufer**, C Blex, R Schindler, GJ Jungehulsing, S Knüppel, M Kreutzträger, A Ekkernkamp, U Dirnagl, SM Strittmatter, A Niedeggen, JM Schwab BMJ open 6 (7), e010651	2016	

439	A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer D Dauch, R Rudalska, G Cossa, JC Nault, TW Kang, T Wuestefeld, A Hohmeyer, S Imbeaud, T Yevsa, L Hoenicke, T Pantsar, P Bozko, NP Malek, T Longerich, **S Laufer**, A Poso, J Zucman-Rossi, M Eilers, L Zender Nature medicine 22 (7), 744-753	2016	
438	Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity A Guţoaia, L Schuster, S Margutti, **S Laufer**, B Schlosshauer, R Krastev, D Stoll, H Hartmann Carbohydrate polymers 143, 25-34	2016	
437	Salinomycin, a candidate drug for the salinomycin, a candidate drug for the elimination of cancer stem cells elimination of cancer stem cells C Naujokat, **S Laufer** Role of Cancer Stem Cells in Cancer Biology and Therapy 227	2016	
436	Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity B Schlosshauer, D Stoll, H Hartmann, L Schuster, R Krastev, S Margutti, **S Laufer** Carbohydrate polymers 143	2016	
435	From enzyme to whole blood: sequential screening procedure for identification and evaluation of p38 MAPK inhibitors SM Bauer, JM Kubiak, U Rothbauer, **S Laufer** Kinase Screening and Profiling: Methods and Protocols, 123-148	2016	
434	Fucoxanthin induced suicidal death of human erythrocytes M Briglia, S Calabró, E Signoretto, K Alzoubi, **S Laufer**, C Faggio, F Lang Cellular Physiology and Biochemistry 37 (6), 2464-2475	2015	
433	Targeting the gatekeeper MET146 of C-Jun N-terminal kinase 3 induces a bivalent halogen/chalcogen bond A Lange, M Günther, FM Büttner, MO Zimmermann, J Heidrich, S Hennig, S Zahn, C Schall, a Sievers-Engler, F Ansideri, P Koch, M Laemmerhofer, T Stehle, **SA Laufer**, FM Boeckler Journal of the American Chemical Society 137 (46), 14640-14652	2015	
432	The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors S Sabatini, G Manfroni, ML Barreca, SM Bauer, M Gargaro, R Cannalire, A Astolfi, J Brea, C Vacca, M Pirro, S Massari, O Tabarrini, MI Loza, F Fallarino, **SA Laufer**, V Cecchetti Chemical biology & drug design 86 (4), 531-545	2015	
431	Triggering of suicidal erythrocyte death by ruxolitinib	2015	

	M Briglia, A Fazio, C Faggio, **S Laufer**, K Alzoubi, F Lang Cellular Physiology and Biochemistry 37 (2), 768-778		
430	c-Jun *N*-terminal kinase inhibitors: a patent review (2010 – 2014) M Gehringer, F Muth, P Koch, **SA Laufer** Expert opinion on therapeutic patents 25 (8), 849-872	2015	
429	Anti-inflammatory activities of phenoxyphenyl ureas mediated by inhibition of p38 kinase R Kulkarni, S Diwyani, **S Laufer**, C VM, P Gurav, P Habbu Current Enzyme Inhibition 11 (2), 116-123	2015	
428	Impact of p38 MAP kinase inhibitors on LPS-induced release of TNF-α in whole blood and primary cells from different species S Fehr, A Unger, E Schaeffeler, S Herrmann, **S Laufer**, M Schwab, W Albrecht Cellular Physiology and Biochemistry 36 (6), 2237-2249	2015	
427	Triggering of suicidal erythrocyte death following boswellic acid exposure S Calabrò, K Alzoubi, C Faggio, **S Laufer**, F Lang Cellular Physiology and Biochemistry 37 (1), 131-142	2015	
426	New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky, H Gerhardt, M Lämmerhofer, M Kohout, M Gehringer, **S Laufer**, M Pink, S Schmitz-Spanke, C Strube, A Kaiser Amino Acids 47, 1155-1166	2015	
425	Role of p38 mitogen-activated protein kinase in linking stearoyl-CoA desaturase-1 activity with endoplasmic reticulum homeostasis A Koeberle, C Pergola, H Shindou, SC Koeberle, T Shimizu, **SA Laufer**, O Werz The FASEB Journal 29 (6), 2439-2449	2015	
424	Effect of TGFβ on calcium signaling in megakaryocytes J Yan, E Schmid, A Almilaji, E Shumilina, O Borst, **S Laufer,** M Gawaz, F Lang Biochemical and Biophysical Research Communications 461 (1), 8-13	2015	
423	Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors M Juchum, M Günther, **SA Laufer** Drug Resistance Updates 20, 12-28	2015	
422	Influence of annexin A7 on insulin sensitivity of cellular glucose uptake	2015	

	D Luo, A Fajol, AT Umbach, AA Noegel, **S Laufer,** F Lang, M Föller Pflügers Archiv-European Journal of Physiology 467, 641-649		
421	Proteinkinase-Inhibitoren: selektiv und wirksam A Freitag, **S Laufer** Nachrichten aus der Chemie 63 (4), 420-425	2015	
420	Flavonoids inhibit COX-1 and COX-2 enzymes and cytokine/chemokine production in human whole blood D Ribeiro, M Freitas, SM Tomé, AMS Silva, **S Laufer**, JLFC Lima, E Fernandes Inflammation 38, 858-870	2015	
419	Solution-phase parallel synthesis of Ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed Azide–Alkyne cycloaddition M Gehringer, M Forster, **SA Laufer** ACS Combinatorial Science 17 (1), 5-10	2015	
418	*Tetra*-Substituted Pyridinylimidazoles As Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and c-Jun *N*-Terminal Kinase 3 for Potential Treatment of … F Muth, M Günther, SM Bauer, E Döring, S Fischer, J Maier, P Drückes, J Köppler, J Trappe, U Rothbauer, P Koch, **SA Laufer** Journal of medicinal chemistry 58 (1), 443-456	2015	
417	Advancing the kinase field: new targets and second generation inhibitors **S Laufer,** J Bajorath Journal of Medicinal Chemistry 58 (1), 1-1	2015	
416	Development of first lead structures for phosphoinositide 3-kinase-C2γ inhibitors A Freitag, P Prajwal, A Shymanets, C Harteneck, B Nürnberg, C Schächtele, M Kubbutat, F Trotzke, **SA Laufer** Journal of medicinal chemistry 58 (1), 212-221	2015	
415	Inhibitors of c-Jun N-terminal kinases: an update P Koch, M Gehringer, **SA Laufer** Journal of medicinal chemistry 58 (1), 72-95	2015	
414	New Frontiers in Kinases: Second Generation Inhibitors–Going beyond Cancer **S Laufer** ACS Medicinal Chemistry Letters 6 (1), 1-1	2015	
413	An optimized and versatile synthesis to pyridinylimidazole-type p38α mitogen activated protein kinase inhibitors A El-Gokha, **SA Laufer**, P Koch	2015	

	Organic & Biomolecular Chemistry 13 (43), 10699-10704		
412	Design and synthesis of novel quinazoline derivatives and their evaluation as PI3Ks inhibitors OM El-Said, MM Hamed, **S Laufer**, AH Abadi Chemical and Pharmaceutical Bulletin 62 (12), 1166-1172	2014	
411	Antinociceptive, anti-inflammatory and gastroprotective effects of a hydroalcoholic extract from the leaves of Eugenia punicifolia (Kunth) DC. in rodents RT Basting, CM Nishijima, JA Lopes, RC Santos, LL Périco, **S Laufer**, S Bauer, MF Costa, LC Santos, LRM Rocha, W Vilegas, ARS Santos, C Dos Santos, CA Hiruma-Lima Journal of ethnopharmacology 157, 257-267	2014	
410	Novel Hinge-Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure–Activity Relationship Study on Tofacitinib Bioisosteres M Gehringer, M Forster, E Pfaffenrot, SM Bauer, **SA Laufer** ChemMedChem 9 (11), 2516-2527	2014	
409	Anti-inflammatory macrolides to manage chronic neutrophilic inflammation M Burnet, JH Guse, HJ Gutke, L Guillot, **S Laufer,** U Hahn, MP Seed, E Vallejo, M Eggers, D McKenzie, W Albrecht, MJ Parnham Macrocycles in Drug Discovery, 206-234	2014	
408	Monitoring of therapeutic Cathepsin B inhibition of in vivo by a specific activateable optical probe and ex vivo by active site labeling J Schwenck, A Maurer, K Fuchs, CM Griessinger, D Bukala, H Kalbacher, B Fehrenbacher, **S Laufer**, M Roecken, C la Fougere, BJ Pichler, M Kneilling EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 41, S411-S412	2014	
407	*In vivo* RNAi screening identifies a mechanism of sorafenib resistance in liver cancer R Rudalska, D Dauch, T Longerich, K McJunkin, T Wuestefeld, TW Kang, A Hohmeyer, M Pesic, J Leibold, A Von Thun, P Schirmacher, J Zuber, KH Weiss, S Powers, NP Malek, M Eilers, B Sipos, SW Lowe, R Geffers, **S Laufer**, L Zender Nature medicine 20 (10), 1138-1146	2014	
406	Effect of TGFβ on Na+/K+ ATPase activity in megakaryocytes Z Hosseinzadeh, E Schmid, E Shumilina, **S Laufer**, O Borst, M Gawaz, F Lang Biochemical and Biophysical Research Communications 452 (3), 537-541	2014	

405	Compostos 2-cloro-4-anilinoquinazolinicos inibidores de proteínas Tirosina cinases, composições farmacêuticas compreendendo os mesmos, processo para sua produção e método para … CMR Sant'Anna, EJL Barreiro, LM Lima, MLC Barbosa, R Tesch, **SA Laufer** Brasil	2014	
404	C-Jun N-terminal kinase 3 (JNK3) as target for halogen bonding A Lange, M Guenther, **SA Laufer**, FM Boeckler ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 248	2014	
403	Modeling of compound profiling experiments using support vector machines J Balfer, K Heikamp, **S Laufer**, J Bajorath Chemical Biology & Drug Design 84 (1), 75-85	2014	
402	Discovery of a Novel Series of Tetrahydro-β-carbolines Inducing Autophagic Cell Death in Human Metastatic Melanoma NS Ahmed, M Elgendy, **S Laufer**, AH Abadi Archiv der Pharmazie 347 (6), 398-406	2014	
401	Four New Flavonol Glycosides from the Leaves of *Brugmansia suaveolens* F Geller, R Murillo, L Steinhauser, B Heinzmann, K Albert, I Merfort, **S Laufer** Molecules 19 (5), 6727-6736	2014	
400	Extract from gum resin of Boswellia serrata decreases [IA. sub. 2]-antibody in a patient with" Late onset Autoimmune Diabetes of the Adult"(LADA) E Schrott, **S Laufer**, M Lammerhofer, HPT Ammon Phytomedicine: International Journal of Phytotherapy & Phytopharmacology 21	2014	
399	p38 MAPK inhibitors: a patent review (2012–2013) S Bühler, **SA Laufer** Expert opinion on therapeutic patents 24 (5), 535-554	2014	
398	A p38 substrate-specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of … R Anton, SM Bauer, PR Keck, **S Laufer**, U Rothbauer PloS one 9 (4), e95641	2014	
397	2-(3-{(3R, 4R)-4-Methyl-3-[methyl (7H-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] piperidin-1-yl} oxetan-3-yl) acetonitrile monohydrate M Gehringer, E Pfaffenrot, P Keck, D Schollmeyer, **SA Laufer** Acta Crystallographica Section E: Structure Reports Online 70 (4), o382-o383	2014	

396	New frontiers in kinases: second generation inhibitors **S Laufer**, J Bajorath Journal of Medicinal Chemistry 57 (6), 2167-2168	2014	
395	Interference of boswellic acids with the ligand binding domain of the glucocorticoid receptor T Scior, M Verhoff, I Gutierrez-Aztatzi, HPT Ammon, **S Laufer**, O Werz Journal of chemical information and modeling 54 (3), 978-986	2014	
394	Specific inhibition of p38-MAPK signaling suppresses experimental arthritis and inflammation induced hypoxia P Guenthoer, K Fuchs, D Lamparter, G Reischl, S Aidone, M Koenig, **S Laufer**, M Roecken, BJ Pichler, M Kneilling EXPERIMENTAL DERMATOLOGY 23 (3), E29-E29	2014	
393	Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA … DA Koch, RBM Silva, AH de Souza, CE Leite, NF Nicoletti, MM Campos, **S Laufer**, FB Morrone Rheumatology 53 (3), 425-432	2014	
392	Back Cover: Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes (ChemMedChem 2/2014) M Gehringer, E Pfaffenrot, S Bauer, **SA Laufer** ChemMedChem 9 (2), 412-412	2014	
391	Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes M Gehringer, E Pfaffenrot, S Bauer, **SA Laufer** ChemMedChem 9 (2), 277-281	2014	
390	Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds **S Laufer**, W Albrecht US Patent 8,633,312	2014	
389	Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors ML de Castro Barbosa, LM Lima, R Tesch, CMR Sant'Anna, F Totzke, MHG Kubbutat, C Schaechtele, **SA Laufer**, EJ Barreiro European journal of medicinal chemistry 71, 1-14	2014	
388	Metabolism of a novel skepinone l-like p38 mitogen-activated protein kinase inhibitor K Storch, M Gehringer, B Baur, **SA Laufer** MedChemComm 5 (6), 808-815	2014	

387	A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors SM Bauer, M Gehringer, **SA Laufer** Analytical Methods 6 (21), 8817-8822	2014	
386	Multiplex in vivo RNAi screening instructs combination therapies to increase the therapeutic efficacy of the multikinase inhibitor sorafenib R Rudalska, D Dauch, K McJunkin, TW Kang, T Wuestefeld, R Geffers, P Schirmacher, S Lowe, T Longerich, **S Laufer**, L Zender Zeitschrift für Gastroenterologie 52 (01), P_4_31	2014	
385	A New *In Vitro* Model to Study Cellular Responses after Thermomechanical Damage in Monolayer Cultures A Hettler, S Werner, S Eick, **S Laufer**, F Weise PLoS One 8 (12), e82635	2013	
384	*Entada africana* fraction CH_2Cl_2/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by … BA Owona, NF Njayou, **SA Laufer**, HJ Schluesener, PF Moundipa BMC Complementary and Alternative Medicine 13, 1-7	2013	
383	Metabolically Stable Dibenzo[*b*,*e*]oxepin-11(6*H*)-ones as Highly Selective p38 MAP Kinase Inhibitors: Optimizing Anti-Cytokine Activity in Human Whole Blood B Baur, K Storch, KE Martz, MI Goettert, A Richters, D Rauh, **SA Laufer** Journal of medicinal chemistry 56 (21), 8561-8578	2013	
382	Effects of a Combined Cyclooxygenase/Lipoxygenase Inhibitor in Pancreatic Cancer HMA Kader, N Nalin, M El-Zeiry, **S Laufer,** TE Adrian PANCREAS 42 (8), 1357-1357	2013	
381	Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib R Ramer, U Walther, P Borchert, **S Laufer**, M Linnebacher, B Hinz Journal of lipid research 54 (11), 3116-3129	2013	
380	Choline and tromethamine salt of licofelone W Albrecht, HG Striegel, **S Laufer** US Patent 8,519,155	2013	
379	A fraction of stem bark extract of Entada africana suppresses lipopolysaccharide-induced inflammation in RAW 264.7 cells BA Owona, NF Njayou, **S Laufer**, PF Moundipa, HJ Schluesener Journal of ethnopharmacology 149 (1), 162-168	2013	

378	Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation O Borst, B Walker, P Münzer, A Russo, E Schmid, C Faggio, B Bigalke, **S Laufer**, M Gawaz, F Lang Cellular Physiology and Biochemistry 31 (6), 914-924	2013	
377	tert-Butyl N-[(3R, 4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl]-N-methylcarbamate M Gehringer, M Forster, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 69 (6), o935-o935	2013	
376	Drug discovery: a modern decathlon **S Laufer**, U Holzgrabe, D Steinhilber Angewandte Chemie International Edition 52 (15), 4072-4076	2013	
375	Arzneistoffentwicklung, ein moderner Zehnkampf **S Laufer**, U Holzgrabe, D Steinhilber Angewandte Chemie 125 (15), 4164-4168	2013	
374	Deoxyhypusine Hydroxylase from *Plasmodium vivax*, the Neglected Human Malaria Parasite: Molecular Cloning, Expression and Specific Inhibition by the 5-LOX … VA Atemnkeng, M Pink, S Schmitz-Spanke, XJ Wu, LL Dong, KH Zhao, C May, **S Laufer,** B Langer, A Kaiser PLoS One 8 (3), e58318	2013	
373	Design, Synthesis and Characterization of N', N"-Diaryl Ureas as p38 Kinase Inhibitors R G Kulkarni, **S Laufer**, C Mangannavar, A Garlapati Medicinal Chemistry 9 (2), 213-221	2013	
372	Salinomycin, a candidate drug for the elimination of cancer stem cells C Naujokat, **S Laufer** Role of Cancer Stem Cells in Cancer Biology and Therapy	2013	
371	Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding A Koeberle, H Shindou, SC Koeberle, **SA Laufer,** T Shimizu, O Werz Proceedings of the National Academy of Sciences 110 (7), 2546-2551	2013	
370	Targeting cancer stem cells with defined compounds and drugs C Naujokata, **S Laufer** Journal of Cancer Research Updates 2 (1), 36-67	2013	
369	Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity	2013	

	S Fischer, HK Wentsch, SC Mayer-Wrangowski, M Zimmermann, SM Bauer, K Storch, R Niess, SC Koeberle, C Grütter, FM Boeckler, D Rauh, **S Laufer** Journal of medicinal chemistry 56 (1), 241-253		
368	tert-Butyl-(3R, 4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl (methyl)-carbamate **S Laufer**, M Gehringer, M Forster Acta Crystallographica Section E 69	2013	
367	Assessing the target differentiation potential of imidazole-based protein kinase inhibitors D Dimova, P Iyer, M Vogt, F Totzke, MHG Kubbutat, C Schächtele, **S Laufer**, J Bajorath Journal of Medicinal Chemistry 55 (24), 11067-11071	2012	
366	2-[5-Bromo-1-(3-chlorobenzyl)-2-methyl-1H-indol-3-yl] acetic acid M Elkady, P Keck, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (12), o3396-o3396	2012	
365	3-(4-Bromophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde M Elkady, P Keck, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (12), o3397-o3397	2012	
364	Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX M Elkady, R Nieß, AM Schaible, J Bauer, S Luderer, G Ambrosi, O Werz, **SA Laufer** Journal of medicinal chemistry 55 (20), 8958-8962	2012	
363	A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors R Selig, M Goettert, V Schattel, D Schollmeyer, W Albrecht, **S Laufer** Journal of Medicinal Chemistry 55 (19), 8429-8439	2012	
362	Discovery of Novel Orally Active Anti-Inflammatory *N*-Phenylpyrazolyl-*N*-Glycinyl-Hydrazone Derivatives That Inhibit TNF-α Production RB Lacerda, LL Da Silva, CKF de Lima, E Miguez, ALP Miranda, **SA Laufer**, EJ Barreiro, CAM Fraga Public Library of Science 7 (10), e46925	2012	
361	1-[(3RS, 4RS)-1-Benzyl-4-methylpiperidin-3-yl]-1, 6-dihydroimidazo [4, 5-d] pyrrolo [2, 3-b] pyridine hemihydrate E Pfaffenrot, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (10), o3052-o3052	2012	

360	N-[(3RS, 4RS)-1-Benzyl-4-methylpiperidin-3-yl]-5-nitro-1-phenylsulfonyl-1H-pyrrolo [2, 3-b] pyridine-4-amine E Pfaffenrot, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (10), o3051-o3051	2012	
359	N-[(3RS, 4SR)-1-Benzyl-4-methylpiperidin-3-yl]-1-(4-methylphenylsulfonyl)-5-nitro-1H-pyrrolo [2, 3-b] pyridin-4-amine E Pfaffenrot, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (10), o3000-o3000	2012	
358	Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors KE Martz, A Dorn, B Baur, V Schattel, MI Goettert, SC Mayer-Wrangowski, D Rauh, **SA Laufer** Journal of medicinal chemistry 55 (17), 7862-7874	2012	
357	On the Reaction of Triphenylphosphane with Thionyl Chloride HF Klein, A Kuhn, N Kuhn, **S Laufer**, M Ströbele Zeitschrift für anorganische und allgemeine Chemie 638 (11), 1784-1786	2012	
356	4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-1H-pyrazol-5-amine B Abu Thaher, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (9), o2603-o2603	2012	
355	PRE-CONDITIONED MAPK ACTIVATED PROTEIN KINASE-2 (MK-2) RESPONSES OF MACROPHAGES TO p38 INHIBITION IN THE ABSENCE OF INTRACELLULAR INHIBITOR, SB203580 N Yousaf, N Malik, M Lees, V Moradi, **S Laufer**, W Albrecht, G Schett, M Burnett, M Seed INFLAMMATION RESEARCH 61, S24-S24	2012	
354	The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA … S Tavolari, A Munarini, G Storci, **S Laufer**, P Chieco, T Guarnieri Cancer letters 321 (2), 187-194	2012	
353	Identification of new γ-hydroxybutenolides that preferentially inhibit the activity of mPGES-1 R De Simone, I Bruno, R Riccio, K Stadler, J Bauer, AM Schaible, **S Laufer**, O Werz Bioorganic & medicinal chemistry 20 (16), 5012-5016	2012	
352	Anti-Inflammatory drug discovery JI Levin, **S Laufer**	2012	

	Royal Society of Chemistry		
351	Dual Inhibition of Phosphodiesterase-4 and p38 MAP Kinase: A Strategy for Treatment of Chronic Inflammatory Diseases W ALBRECHT, **S LAUFER** Anti-Inflammatory Drug Discovery, 137	2012	
350	Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury MA Kopp, T Liebscher, A Niedeggen, **S Laufer**, B Brommer, GJ Jungehulsing, SM Strittmatter, U Dirnagl, JM Schwab Cell and tissue research 349 (1), 119-132	2012	
349	Development of a p38δ mitogen activated protein kinase ELISA assay for the quantitative determination of inhibitor activity M Goettert, N Shaalan, R Graeser, **SA Laufer** Journal of pharmaceutical and biomedical analysis 66, 349-351	2012	
348	Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase SC Koeberle, S Fischer, D Schollmeyer, V Schattel, C Grütter, D Rauh, **SA Laufer** Journal of medicinal chemistry 55 (12), 5868-5877	2012	
347	Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action M Fronza, E Lamy, S Günther, B Heinzmann, **S Laufer**, I Merfort Phytochemistry 78, 107-119	2012	
346	{*n*BuMg(O*R*)}$_2$ and {Mg(O*R*)$_2$}$_2$ (*R* = 2, 4, 6-*t*Bu$_3$C$_6$H$_2$) – Sterically Congested Magnesium Alcoholates U Flörke, G Henkel, A Kuhn, N Kuhn, **S Laufer**, C Maichle-Mößmer Zeitschrift für anorganische und allgemeine Chemie 638 (5), 730-732	2012	
345	4-[5-Amino-4-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl] benzonitrile B Abu Thaher, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (4), o935-o935	2012	
344	2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors M Burnet, **S Laufer**, P Koch US Patent 8,143,294	2012	
343	Inferential NMR/X-ray-Based Structure Determination of a Dibenzo[*a*,*d*]cycloheptenone Inhibitor–p38α MAP Kinase Complex in Solution	2012	

	VS Honndorf, N Coudevylle, **S Laufer**, S Becker, C Griesinger, M Habeck Angewandte Chemie International Edition 51 (10), 2359-2362		
342	Ethyl 5-amino-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-1H-pyrazole-4-carboxylate dimethyl sulfoxide hemisolvate BA Thaher, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (Pt 3), o917	2012	
341	4-(4-Fluorophenyl)-1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine B Abu Thaher, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (3), o632-o632	2012	
340	Ethyl 5-amino-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-1H-pyrazole-4-carboxylate dimethyl sulfoxide hemisolvate B Abu Thaher, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (3), o917-o918	2012	
339	4-(4-Fluorophenyl)-1-(4-nitrophenyl)-3-(pyridin-4-yl)-1H-pyrazol-5-amine B Abu Thaher, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 68 (3), o633-o633	2012	
338	Therapeutic Potential of Small Molecules Modulating the Cyclooxygenase–5-Lipoxygenase Pathway W Albrecht, **S Laufer** Polypharmacology in Drug Discovery, 383-408	2012	
337	Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from novel microvascular wall models G Juchem, DR Weiss, M Knott, A Senftl, S Förch, T Fischlein, E Kreuzer, B Reichart, **S Laufer**, S Nees American Journal of Physiology-Heart and Circulatory Physiology 302 (3), H567-H581	2012	
336	A Multicomponent Carba-Betti Strategy to Alkylidene Heterodimers–Total Synthesis and Structure–Activity Relationships of Arzanol A Minassi, L Cicione, A Koeberle, J Bauer, **S Laufer**, O Werz, G Appendino European journal of organic chemistry 2012 (4), 772-779	2012	
335	Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor SC Koeberle, J Romir, S Fischer, A Koeberle, V Schattel, W Albrecht, C Grütter, O Werz, D Rauh, T Stehle, **SA Laufer** Nature chemical biology 8 (2), 141-143	2012	

334	Tri-and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases BA Thaher, M Arnsmann, F Totzke, JE Ehlert, MHG Kubbutat, C Schächtele, MO Zimmermann, P Koch, FM Boeckler, **SA Laufer** Journal of Medicinal Chemistry 55 (2), 961-965	2012	
333	Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis L Graziosi, A Mencarelli, C Santorelli, B Renga, S Cipriani, E Cavazzoni, G Palladino, **S Laufer**, M Burnett, A Donini, S Fiorucci European journal of pharmacology 674 (2-3), 143-152	2012	
332	p38α mitogen-activated protein kinase inhibitors, a patent review (2005–2011) S Fischer, SC Koeberle, **SA Laufer** Expert opinion on therapeutic patents 21 (12), 1843-1866	2011	
331	The application of Stille cross-coupling reactions with multiple nitrogen containing heterocycles R Selig, D Schollmeyer, W Albrecht, **S Laufer** Tetrahedron 67 (47), 9204-9213	2011	
330	Polymorphic form of 6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1h-pyrrolizin-5-ylacetic acid W Albrecht, T Kammermeier, HG Striegel, P Merckle, **S Laufer** US Patent 8,034,837	2011	
329	1, 4-Dimethyl-2-phenyl-6, 7-dihydro-1H-pyrazolo [4, 3-b] pyridine-3, 5 (2H, 4H)-dione M Weisser, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 67 (10), o2586-o2586	2011	
328	6-(4-Chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-carbaldehyde P Keck, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 67 (9), o2292-o2292	2011	
327	6-(4-Methoxyphenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-carbaldehyde P Keck, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 67 (9), o2417-o2417	2011	
326	In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica M Fronza, R Murillo, S Ślusarczyk, M Adams, M Hamburger, B Heinzmann, **S Laufer**, I Merfort	2011	

	Bioorganic & medicinal chemistry 19 (16), 4876-4881		
325	Four new kaempferol glycosides from the leaves of Brugmansia suaveolens F Geller, R Murillo, L Steinhauser, B Heinzmann, K Albert, I Merfort, **S Laufer** Planta Medica 77 (12), PG62	2011	
324	Alkoxymagnesium Iodide Complexes P Haiss, A Kuhn, N Kuhn, C Maichle-Mößmer, **S Laufer**, M Steimann, KP Zeller European Journal of Inorganic Chemistry 2011 (22), 3284-3287	2011	
323	Structural and Conformational Analysis of Proanthocyanidins from *Parapiptadenia rigida* and Their Wound-Healing Properties CA Schmidt, R Murillo, B Heinzmann, **S Laufer**, V Wray, I Merfort Journal of natural products 74 (6), 1427-1436	2011	
322	Chiral sulfoxides as metabolites of 2-thioimidazole-based p38α mitogen-activated protein kinase inhibitors: Enantioselective synthesis and biological evaluation S Bühler, M Goettert, D Schollmeyer, W Albrecht, **SA Laufer** Journal of medicinal chemistry 54 (9), 3283-3297	2011	
321	A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3 M Goettert, S Luik, R Graeser, **SA Laufer** Journal of pharmaceutical and biomedical analysis 55 (1), 236-240	2011	
320	Cell receptor-ligand interaction, signalling, activation and apoptosis: 21. Pregnenolone Sulphate is Similar to Dexamethasone in Supressing the Unfettered Secretion of … C Ciurtin, Y Majeed, J Naylor, P Sukumar, A English, P Emery, D Beech Rheumatology 50 (suppl_3), iii50-iii52	2011	
319	Modeling and benchmark data set for the inhibition of c-Jun N-terminal kinase-3 V Schattel, G Hinselmann, A Jahn, A Zell, **S Laufer** Journal of chemical information and modeling 51 (3), 670-679	2011	
318	Design, Synthesis and Structure–Activity Relationship of Functionalized Tetrahydro-**β**-carboline Derivatives as Novel PDE5 Inhibitors NS Ahmed, BD Gary, HN Tinsley, GA Piazza, **S Laufer**, AH Abadi Archiv der Pharmazie 344 (3), 149-157	2011	
317	Transient exposure of macrophages to P38 map kinase inhibition conditions cell responses through MAPK activated protein kinase-2 regulation N Malik, M Lees, V Moradi, **S Laufer**, G Schett, M Burnet, M Seed	2011	

	Annals of the Rheumatic Diseases 70 (Suppl 2), A17-A17		
316	3-(2, 4-Difluoroanilino)-9-nitrodibenzo [b, e] oxepin-11 (6H)-one B Baur, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 67 (3), o555-o555	2011	
315	3-(2, 4-Dimethoxyanilino)-8-methoxydibenz [b, e] oxepin-11 (6H)-one B Baur, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 67 (2), o487-o487	2011	
314	Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from 2 novel microvascular wall models 3 EK Fischlein, B Reichart, **S Laufer**, S Nees	2011	
313	Conformational effects on potency of thioimidazoles and dihydrothiazolines R Selig, V Schattel, M Goettert, D Schollmeyer, W Albrecht, **S Laufer** MedChemComm 2 (4), 261-269	2011	
312	Catechin Derivatives from *Parapiptadenia rigida* with *in Vitro* Wound-Healing Properties CA Schmidt, R Murillo, T Bruhn, G Bringmann, M Goettert, B Heinzmann, V Brecht, **SA Laufer**, I Merfort Journal of natural Products 73 (12), 2035-2041	2010	
311	Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids M Goettert, V Schattel, P Koch, I Merfort, **S Laufer** Chembiochem 11 (18), 2579-2588	2010	
310	N-(4-Chloropyridin-2-yl)-N-(4-methylphenylsulfonyl) acetamide S Bühler, D Schollmeyer, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (12), o3320-o3320	2010	
309	N-(4-Chloropyridin-2-yl)-N-methoxymethyl-4-methylbenzenesulfonamide S Bühler, D Schollmeyer, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (12), o3321-o3321	2010	
308	Tri-and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors	2010	

	S Laufer, D Hauser, T Stegmiller, C Bracht, K Ruff, V Schattel, W Albrecht, P Koch Bioorganic & medicinal chemistry letters 20 (22), 6671-6675		
307	Optimization of a nonradioactive immunosorbent assay for p38α mitogen-activated protein kinase activity M Goettert, R Graeser, **SA Laufer** Analytical biochemistry 406 (2), 233-234	2010	
306	A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors N S Ahmed, B D Gary, G A Piazza, H N Tinsley, **S Laufer**, A H Abadi Medicinal Chemistry 6 (6), 374-387	2010	
305	2-sulfinyl-and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors W Albrecht, C Greim, HG Striegel, K Tollmann, P Merkle, **S Laufer** US Patent App. 11/817,298	2010	
304	Cytotoxic abietane diterpenes from Peltodon longipes and their mode of action M Fronza, S Günther, R Murillo, E Lamy, B Heinzmann, **S Laufer**, I Merfort Planta Medica 76 (12), SL_22	2010	
303	Catechin derivatives from Parapiptadenia rigida: biological studies and conformational analysis C Schmidt, M Fronza, R Murillo, V Wray, G Bringmann, T Bruhn, B Heinzmann, **S Laufer**, I Merfort Planta Medica 76 (12), O_1	2010	
302	Rosmarinic acid as the effective compound in Cordia americana F Geller, C Schmidt, M Goettert, M Fronza, B Heinzmann, O Werz, I Merfort, **S Laufer** Planta Medica 76 (12), P584	2010	
301	One-pot synthesis of 4, 6-diaryl-2-oxo (imino)-1, 2-dihydropyridine-3-carbonitrile; a new scaffold for p38α MAP Kinase Inhibition AM Serry, S Luik, **S Laufer**, AH Abadi Journal of Combinatorial Chemistry 12 (4), 559-565	2010	
300	Inside Cover: Synthesis and Biological Testing of *N*-Aminoimidazole-Based p38α MAP Kinase Inhibitors (ChemMedChem 7/2010) C Bracht, DRJ Hauser, V Schattel, W Albrecht, **SA Laufer** ChemMedChem 5 (7), 966-966	2010	
299	Synthesis and Biological Testing of *N*-Aminoimidazole-Based p38α MAP Kinase Inhibitors	2010	

	C Bracht, DRJ Hauser, V Schattel, W Albrecht, **SA Laufer** ChemMedChem 5 (7), 1134-1142		
298	Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1β-stimulated human chondrocytes H Joos, W Albrecht, **S Laufer**, RE Brenner British journal of pharmacology 160 (5), 1252-1262	2010	
297	2-(Bicyclo [2.2. 1] hept-5-en-2-yl)-1H-pyrrolo [2, 3-b] pyridine R Selig, D Schollmeyer, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (7), o1800-o1800	2010	
296	N-{2-Methyl-5-[(5-oxo-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-yl) amino] phenyl} benzamide A Dorn, D Schollmeyer, **SA Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (7), o1867-o1867	2010	
295	Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: Pyridinylimidazol-2-ones as novel potent p38α mitogen-activated protein kinase inhibitors P Koch, **S Laufer** Journal of medicinal chemistry 53 (12), 4798-4802	2010	
294	Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle L Munoz, EE Ramsay, M Manetsch, Q Ge, C Peifer, **S Laufer**, AJ Ammit European journal of pharmacology 635 (1-3), 212-218	2010	
293	Fluorescence polarization binding assay to develop inhibitors of inactive p38α mitogen-activated protein kinase L Munoz, R Selig, YT Yeung, C Peifer, D Hauser, **S Laufer** Analytical biochemistry 401 (1), 125-133	2010	
292	Design, synthesis and SAR of phenylamino-substituted 5, 11-dihydro-dibenzo [a, d] cyclohepten-10-ones and 11H-dibenzo [b, f] oxepin-10-ones as p38 MAP kinase inhibitors A Dorn, V Schattel, **S Laufer** Bioorganic & medicinal chemistry letters 20 (10), 3074-3077	2010	
291	2-(4-Fluorophenyl)-N-{4-[6-(4-fluorophenyl)-2, 3-dihydroimidazo [2, 1-b][1, 3] thiazol-5-yl] pyridin-2-yl} acetamide R Selig, D Schollmeyer, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (5), o1132-o1132	2010	

290	N-[3-(5-Oxo-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-ylamino) phenyl] furan-3-carboxamide A Dorn, D Schollmeyer, **SA Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (5), o1100-o1100	2010	
289	1-[4-(2-Aminoanilino) phenyl]-2, 2, 2-trifluoroethanone A Dorn, D Schollmeyer, **SA Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (5), o1149-o1149	2010	
288	Annellated pyrrole compounds for cancer management **S Laufer**, T Guarnieri, S Tavolari, V Tomasi, E Palazzini, M Barbanti US Patent App. 12/375,305	2010	
287	Identification of rosmarinic acid as the major active constituent in Cordia americana F Geller, C Schmidt, M Göttert, M Fronza, V Schattel, B Heinzmann, O Werz, EMM Flores, I Merfort, **S Laufer** Journal of ethnopharmacology 128 (3), 561-566	2010	
286	4-Chloro-7-methoxymethyl-2-phenyl-7H-pyrrolo [2, 3-b] pyridine R Selig, D Schollmeyer, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (4), o822-o822	2010	
285	5-(4-Fluorophenyl)-4-(4-pyridyl)-1, 3-oxazol-2-amine P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (4), o917-o917	2010	
284	Imidazole compounds having an antiinflammatory effect W Albrecht, D Hauser, **S Laufer**, HG Striegel, K Tollmann US Patent App. 12/310,305	2010	
283	Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38α mitogen-activated protein kinase inhibitors P Koch, H Jahns, V Schattel, M Goettert, **S Laufer** Journal of medicinal chemistry 53 (3), 1128-1137	2010	
282	7-[4-(4-Fluorophenyl)-2-methylsulfanyl-1H-imidazol-5-yl] tetrazolo [1, 5-a] pyridine R Selig, D Schollmeyer, J Schlosser, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (2), o451-o451	2010	

281	N-{4-[4-(4-Fluorophenyl)-1-methyl-2-[(R)-methylsulfinyl]-1H-imidazol-5-yl]-2-pyridyl} acetamide dihydrate S Bühler, D Schollmeyer, D Hauser, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 66 (1), o121-o121	2010	
280	Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors **S Laufer**, S Luik Cyclooxygenases: Methods and Protocols, 91-116	2010	
279	M1739 Ml3403, a New p38 MAPK Inhibitor, Corrects Immune Dysfunction in Rodent Models of Chronic Inflammatory Disorders S Fiorucci, **SA Laufer**, A Mencarelli, B Renga, C Booth, GL Tudor, E Distrutti, M Burnet Gastroenterology 5 (138), S-409	2010	
278	3, 4-Diaryl-isoxazoles and-imidazoles as potent dual inhibitors of p38α mitogen activated protein kinase and casein kinase 1δ C Peifer, M Abadleh, J Bischof, D Hauser, V Schattel, H Hirner, U Knippschild, **S Laufer** Journal of medicinal chemistry 52 (23), 7618-7630	2009	
277	Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts M Fronza, B Heinzmann, M Hamburger, **S Laufer**, I Merfort Journal of ethnopharmacology 126 (3), 463-467	2009	
276	Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection C Henneges, D Bullinger, R Fux, N Friese, H Seeger, H Neubauer, **S Laufer**, CH Gleiter, M Schwab, A Zell, B Kammerer BMC cancer 9, 1-11	2009	
275	(2Z)-2-Fluoro-N-{4-[5-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-4-yl]-2-pyridyl}-3-phenylacrylamide R Selig, D Schollmeyer, T Stegmiller, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (12), o3284-o3284	2009	
274	4-Chloro-1-(4-methylphenylsulfonyl)-1H-pyrrolo [2, 3-b] pyridine R Selig, D Schollmeyer, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (12), o3018-o3018	2009	
273	N-{4-[4-(4-Fluorophenyl)-1-(2-methoxyethyl)-2-methylsulfanyl-1H-imidazol-5-yl]-2-pyridyl}-2-methyl-3-phenylpropionamide K Ziegler, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (12), o3128-o3128	2009	

272	2-(3, 4, 5-Trimethoxyphenyl)-1H-pyrrolo [2, 3-b] pyridine R Selig, D Schollmeyer, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (12), o3097-o3097	2009	
271	Accelerated Clearance of *Plasmodium*-infected Erythrocytes in Sickle Cell Trait and Annexin-A7 Deficiency PA Lang, RS Kasinathan, VB Brand, C Duranton, C Lang, S Koka, E Shumilina, DS Kempe, V Tanneur, A Akel, KS Lang, M Föller, JFJ Kun, PG Kremsner, S Wesselborg, **S Laufer**, CS Clemen, C Herr, AA Noegel, T Wieder, E Gulbins, F Lang, SM Huber Cellular Physiology and Biochemistry 24 (5-6), 415-428	2009	
270	2-Acylaminopyridin-4-ylimidazoles as p38 MAP Kinase Inhibitors: Design, Synthesis, and Biological and Metabolic Evaluations K Ziegler, DRJ Hauser, A Unger, W Albrecht, **SA Laufer** ChemMedChem: Chemistry Enabling Drug Discovery 4 (11), 1939-1948	2009	
269	4-(4-Fluorophenyl)-1-methoxymethyl-2-phenyl-1H-imidazole R Selig, D Schollmeyer, W Albrecht, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (11), o2803-o2803	2009	
268	3-(4-Fluorophenyl)-2-(4-pyridyl) pyrido [2, 3-b] pyrazine P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (10), o2546-o2546	2009	
267	N-{4-[3-(4-Fluorophenyl) pyrido [2, 3-b] pyrazin-2-yl]-2-pyridyl} isopropylamine P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (10), o2557-o2557	2009	
266	2-(4-Fluorophenyl)-3-(4-pyridyl) pyrido [2, 3-b] pyrazine P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (10), o2512-o2512	2009	
265	2-[(1-Methyl-1H-pyrrol-2-yl) carbonylmethyl] isoindoline-1, 3-dione J Schlosser, D Schollmeyer, **S Laufer**, C Peifer Acta Crystallographica Section E: Structure Reports Online 65 (10), o2375-o2375	2009	
264	2-thio-substituted imidazole derivatives and their use in pharmaceutics **S Laufer**, HG Striegel, K Tollmann, W Albrecht US Patent 7,582,660	2009	

263	Participation of leukotriene C4 in the regulation of suicidal erythrocyte death M Foller, H Mahmud, S Gu, K Wang, E Floride, Y Kucherenko, S Luik, **S Laufer**, F Lang Acta physiologica Polonica 12 (3), 135	2009	
262	Arylpyrrolizines as Inhibitors of Microsomal Prostaglandin E_2 Synthase-1 (mPGES-1) or as Dual Inhibitors of mPGES-1 and 5-Lipoxygenase (5-LOX) AJ Liedtke, PR Keck, F Lehmann, A Koeberle, O Werz, **SA Laufer** Journal of medicinal chemistry 52 (15), 4968-4972	2009	
261	Novel lead structures for p38 MAP kinase via FieldScreen virtual screening TJ Cheeseright, M Holm, F Lehmann, S Luik, M Gottert, JL Melville, **S Laufer** Journal of medicinal chemistry 52 (14), 4200-4209	2009	
260	3-(4-Fluorophenyl)-6-methoxy-2-(4-pyridyl) quinoxaline H Jahns, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (7), o1626-o1626	2009	
259	Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial … JP Raynauld, J Martel-Pelletier, P Bias, **S Laufer**, B Haraoui, D Choquette, AD Beaulieu, F Abram, M Dorais, E Vignon, JP Pelletier, Canadian Licofelone Study Group Annals of the rheumatic diseases 68 (6), 938-947	2009	
258	4-[3-(4-Fluorophenyl) quinoxalin-2-yl]-N-isopropylpyridin-2-amine P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (6), o1344-o1344	2009	
257	1-[2-(Benzylamino)-4-pyridyl]-2-(4-fluorophenyl) ethane-1, 2-dione H Jahns, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (6), o1451-o1451	2009	
256	Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation E Saulle, R Riccioni, S Coppola, I Parolini, D Diverio, V Riti, G Mariani, **S Laufer**, M Sargiacomo, U Testa British journal of haematology 145 (3), 399-411	2009	
255	Successful structure-based design of recent p38 MAP kinase inhibitors SC Karcher, **SA Laufer** Current Topics in Medicinal Chemistry 9 (7), 655-676	2009	

254	Influence of p38MAPK inhibition on IL-1β-stimulated human chondrocytes: A microarray approach H Joos, W Albrecht, **S Laufer**, RE Brenner International journal of molecular medicine 23 (5), 685-693	2009	
253	Role of the hydrogen bonding heteroatom− Lys53 interaction between the p38α mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors BA Thaher, P Koch, V Schattel, **S Laufer** Journal of medicinal chemistry 52 (8), 2613-2617	2009	
252	Dibenzocycloheptane compounds and pharmaceuticals containing these compounds **S Laufer**, W Albrecht, C Greim, HG Striegel, K Tollmann US Patent App. 11/914,078	2009	
251	Biological studies on Brazilian plants used in wound healing C Schmidt, M Fronza, M Goettert, F Geller, S Luik, EMM Flores, CF Bittencourt, GD Zanetti, BM Heinzmann, **S Laufer**, I Merfort Journal of ethnopharmacology 122 (3), 523-532	2009	
250	Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38MAPK antibodies, kits and their use G Schett, W Albrecht, **S Laufer** US Patent App. 11/871,565	2009	
249	Rapid and easy access to indoles via microwave-assisted Hemetsberger–Knittel synthesis F Lehmann, M Holm, **S Laufer** Tetrahedron Letters 50 (15), 1708-1709	2009	
248	Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors C Peifer, S Bühler, D Hauser, K Kinkel, F Totzke, C Schächtele, **S Laufer** European journal of medicinal chemistry 44 (4), 1788-1793	2009	
247	Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical … SC Karcher, **SA Laufer** Journal of medicinal chemistry 52 (6), 1778-1782	2009	
246	Targeting Proteinkinases: The Selectivity Problem **S LAUFER**, G AHRENS, S KARCHER, R NIESS, J HERING Scientia Pharmaceutica 77 (5), 165	2009	
245	4-[2-(4-Fluorophenyl)-1H-pyrrol-3-yl] pyridine	2009	

	B Abu Thaher, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (3), o457-o457		
244	4-[2-(4-Fluorophenyl) furan-3-yl] pyridine B Abu Thaher, P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (3), o458-o458	2009	
243	Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase **S Laufer**, F Lehmann Bioorganic & Medicinal Chemistry Letters 19 (5), 1461-1464	2009	
242	4-[5-(4-Fluorophenyl)-1H-imidazol-4-yl] pyridine P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 65 (3), o573-o573	2009	
241	Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in … JP Raynauld, J Martel-Pelletier, F Abram, M Dorais, B Haraoui, D Choquette, P Bias, KH Emmert, **S Laufer**, JP Pelletier Arthritis research & therapy 10 (6), 1-8	2008	
240	tert-Butyl N-benzyl-N-(4-methyl-2-pyridyl) carbamate P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 64 (11), o2222-o2222	2008	
239	tert-Butyl N-(4-methyl-2-pyridyl) carbamate P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 64 (11), o2216-o2216	2008	
238	tert-Butyl N-benzyl-N-[4-(4-fluorobenzoylmethyl)-2-pyridyl] carbamate P Koch, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 64 (11), o2221-o2221	2008	
237	Związki pirolizynowe, środek farmaceutyczny i zastosowanie związków pirolizynowych **S Laufer**, K Neher, HG Striegel	2008	
236	2-thio-substituted imidazole derivatives and their use in pharmaceutics **S Laufer**, HG Striegel, W Albrecht, K Tollmann US Patent 7,442,713	2008	

235	Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis D Bullinger, R Fux, G Nicholson, S Plontke, C Belka, **S Laufer**, CH Gleiter, B Kammerer Journal of the American Society for Mass Spectrometry 19, 1500-1513	2008	
234	Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: Synthesis and biological testing of 2-alkylsulfanyl-, 4 (5)-aryl-, 5 (4 … P Koch, C Bäuerlein, H Jank, **S Laufer** Journal of medicinal chemistry 51 (18), 5630-5640	2008	
233	Medizinische Chemie und molekulare Hemmmechanismen der Tyrosinkinase-Inhibitoren. Schwerpunkt pharmazeutischer Forschung M Holm, F Lehmann, **S Laufer** Pharmazie in unserer Zeit 37 (5), 382-392	2008	
232	Metabolic signature of breast cancer cell line MCF–7: Profiling of modified nucleosides via LC-IT MS coupling H Neubauer, D Bullinger, T Fehm, **S Laufer**, C Gleiter, B Kammerer Geburtshilfe und Frauenheilkunde 68 (S 01), PO_Onko_01_19	2008	
231	Metabolische Signatur der Mammakarzinomzell-Linie MCF-7: Profiling modifizierter Nukleoside mittels LC-IT MS H Neubauer, D Bullinger, T Fehm, **S Laufer**, C Gleiter, B Kammerer Senologie-Zeitschrift für Mammadiagnostik und-therapie 5 (03), A103	2008	
230	Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1 A Koeberle, U Siemoneit, U Bühring, H Northoff, **S Laufer**, W Albrecht, O Werz Journal of Pharmacology and Experimental Therapeutics 326 (3), 975-982	2008	
229	Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity **S Laufer**, C Greim, S Luik, SS Ayoub, F Dehner Inflammopharmacology 16, 155-161	2008	
228	Design, synthesis, and biological evaluation of novel Tri-and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: Focus on … **SA Laufer**, DRJ Hauser, DM Domeyer, K Kinkel, AJ Liedtke Journal of medicinal chemistry 51 (14), 4122-4149	2008	

227	Design, Synthesis, and Biological Evaluation of Novel 3-Aryl-4-(1*H*-indole-3yl)-1,5-dihydro-2*H*-pyrrole-2-ones as Vascular Endothelial Growth Factor Receptor … C Peifer, R Selig, K Kinkel, D Ott, F Totzke, C Schächtele, R Heidenreich, M Röcken, D Schollmeyer, **S Laufer** Journal of medicinal chemistry 51 (13), 3814-3824	2008	
226	Methyl 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfanyl] butanoate P Koch, C Bäuerlein, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 64 (7), o1183-o1184	2008	
225	The scratch assay: A suitable in vitro tool for studying wound healing effects M Fronza, F Geller, C Bittencourt, E Flores, B Heinzmann, **S Laufer**, I Merfort Planta Medica 74 (09), PD4	2008	
224	Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer D Bullinger, H Fröhlich, F Klaus, H Neubauer, A Frickenschmidt, C Henneges, A Zell, **S Laufer**, CH Gleiter, H Liebich, B Kammerer Analytica Chimica Acta 618 (1), 29-34	2008	
223	In vitro metabolism of 2-[6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and-2 … W Albrecht, A Unger, AK Nussler, **S Laufer** Drug metabolism and disposition 36 (5), 894-903	2008	
222	Dynamics in the p38α MAP Kinase–SB203580 Complex Observed by Liquid-State NMR Spectroscopy VS Honndorf, N Coudevylle, **S Laufer**, S Becker, C Griesinger Angewandte Chemie 120 (19), 3604-3607	2008	
221	Isoxazolone based inhibitors of p38 MAP kinases **SA Laufer**, S Margutti Journal of medicinal chemistry 51 (8), 2580-2584	2008	
220	Inhibition of GSK3 differentially modulates NF-κB, CREB, AP-1 and β-catenin signaling in hepatocytes, but fails to promote TNF-α-induced apoptosis F Götschel, C Kern, S Lang, T Sparna, C Markmann, J Schwager, S McNelly, F von Weizsäcker, **S Laufer**, A Hecht, I Merfort Experimental cell research 314 (6), 1351-1366	2008	
219	3-(2-Fluorophenyl)-6-(phenoxymethyl)-1, 2, 4-triazolo [3, 4-b][1, 3, 4] thiadiazole M Holm, D Schollmeyer, **S Laufer**	2008	

	Acta Crystallographica Section E: Structure Reports Online 64 (4), o700-o700		
218	6-Amino-1-benzyl-4-(4-chlorophenyl)-3-(4-pyridyl)-1, 4-dihydropyrano [2, 3-c] pyrazole-5-carbonitrile F Lehmann, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 64 (4), o701-o701	2008	
217	The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands C Ospelt, M Kurowska-Stolarska, M Neidhart, BA Michel, RE Gay, **S Laufer**, S Gay Annals of the rheumatic diseases 67 (4), 524-529	2008	
216	Protizápalové oxo-a hydroxyderiváty pyrolizínov a ich použitie vo farmácii **S Laufer**, K Tollmann, HG Striegel	2008	
215	A Software Solution Automatically Assigns Formulae for Construction of Fragmentation Pathways Accelerating Drug Elucidation with ESI-TOF. G Zurek, I Krebs, S Goetz, H Scheible, **S Laufer**, B Kammerer, W Albrecht LC-GC Europe	2008	
214	IL-1β regulates FHL2 and other cytoskeleton-related genes in human chondrocytes H Joos, W Albrecht, **S Laufer**, H Reichel, RE Brenner Molecular medicine 14, 150-159	2008	
213	Implications for selectivity of 3, 4-diarylquinolinones as p38αMAP kinase inhibitors C Peifer, R Urich, V Schattel, M Abadleh, M Röttig, O Kohlbacher, **S Laufer** Bioorganic & medicinal chemistry letters 18 (4), 1431-1435	2008	
212	In vitro metabolism of Licofelone (ML3000), an Inhibitor of Cyclooxygenases-1 and-2 and 5-Lipoxygenase W Albrecht, A Unger, AK Nuessler, **S Laufer** Drug Metabolism and Disposition	2008	
211	Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic … S Tavolari, M Bonafe, M Marini, C Ferreri, G Bartolini, E Brighenti, S Manara, V Tomasi, **S Laufer**, T Guarnieri Carcinogenesis 29 (2), 371-380	2008	

210	4-(4-Fluorophenyl)-2-methyl-3-(1-oxy-4-pyridyl) isoxazol-5 (2H)-one S Margutti, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 64 (2), o504-o504	2008	
209	4-[4-(4-Fluorophenyl)-2-methyl-5-oxo-2, 5-dihydroisoxazol-3-yl]-1-methylpyridinium iodide–4-[3-(4-fluorophenyl)-2-methyl-5-oxo-2, 5-dihydroisoxazol-4-yl]-1-methylpyridinium … S Margutti, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 64 (1), o298-o299	2008	
208	Inhibition of GSK3 differentially modulates NF-? B, CREB, AP-1 and?-catenin signaling in hepatocytes, but fails to promote TNF-?-induced apoptosis F G tschel, C Kern, S Lang, T Sparna, C Markmann, J Schwager, S McNelly, F von Weizsäcker, **S Laufer**, A Hecht, I Merfort Experimental Cell Research 314 (6), 1351-1366	2008	
207	Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients A Frickenschmidt, H Fröhlich, D Bullinger, A Zell, **S Laufer**, CH Gleiter, H Liebich, B Kammerer Biomarkers 13 (4), 435-449	2008	
206	Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research M Holm, F Lehmann, **S Laufer** Pharmazie in unserer Zeit 37 (5), 382-392	2008	
205	A Convenient Synthesis of 1-(4-Fluorophenyl)-2-(4-pyridyl) cyclopentene from Cyclopentanone BA Thaher, P Koch, V Del Amo, P Knochel, **S Laufer** Synthesis 2008 (02), 225-228	2008	
204	Inhibitory effect of inflammatory mediator by Orostachys japonicus in mouse peritoneal macrophages P Koch, JH Guse, M Burnet, **S Laufer** INFLAMMATION RESEARCH 57, S99-S99	2008	
203	Three-component combinatorial synthesis of novel dihydropyrano [2, 3-c] pyrazoles F Lehmann, M Holm, **S Laufer** Journal of Combinatorial Chemistry 10 (3), 364-367	2008	
202	4-aryl-5-heteroaryl-2-thio-substituted imidazoles: Approach to p38 MAP kinase inhibitor prodrugs P Koch, JH Guse, M Burnet, **S Laufer** INFLAMMATION RESEARCH 57, S99-S100	2008	

201	Regiospecific and highly flexible synthesis of 1, 4, 5-trisubstituted 2-sulfanylimidazoles from structurally diverse ethanone precursors **SA Laufer**, DRJ Hauser, AJ Liedtke Synthesis 2008 (02), 253-266	2008	
200	Preconditioning lymphocytes with p38 MAPK inhibitors, and not accessory cells, prevents Con-A-induced lymphocyte responses V Moradi, E Johnson, L Dugo, V Holan, M Burnet, **S Laufer**, M Seed INFLAMMATION RESEARCH 57, S106	2008	
199	Towards the improvement of the synthesis of novel 4 (5)-aryl-5 (4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity **S Laufer**, P Koch Organic & Biomolecular Chemistry 6 (3), 437-439	2008	
198	Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling D Bullinger, H Neubauer, T Fehm, **S Laufer**, CH Gleiter, B Kammerer BMC biochemistry 8, 1-14	2007	
197	2-(6-Amino-7H-purin-7-yl)-1-phenylethanone S Buehler, D Schollmeyer, D Hauser, **S Laufer**, C Peifer Acta Crystallographica Section E: Structure Reports Online 63 (12), o4646-o4647	2007	
196	2-(6-Methoxy-7H-purin-7-yl)-1-phenylethanone monohydrate S Buehler, D Schollmeyer, D Hauser, **S Laufer**, C Peifer Acta Crystallographica Section E: Structure Reports Online 63 (10), o4154-o4155	2007	
195	Are MAP kinases drug targets? Yes, but difficult ones S Margutti, **SA Laufer** ChemMedChem: Chemistry Enabling Drug Discovery 2 (8), 1116-1140	2007	
194	2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry **S Laufer**, D Kotschenreuther, P Merckle, K Tollmann, HG Striegel US Patent 7,253,191	2007	
193	2-(4-Fluorophenyl)-1-(4-pyridyl) cyclopentan-1-ol B Abu Thaher, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 63 (8), o3531-o3531	2007	

192	Chondroprotective effects of licofelone, a fop00728 b-llpvxyutnase and cyclooxygenase inhibitor, vis-a-vis naproxen in knee osteoarthritis (OA): A two-year study using … JP Pelletier, JR Raynauld, P Bias, **S Laufer**, B Haraoui, D Choquette, F Abram, E Vignon, J Martel-Pelletier ANNALS OF THE RHEUMATIC DISEASES 66, 59-59	2007	
191	Isoxazoles as p38 MAPk inhibitors. interaction with atp binding site S Margutti, **S Laufer** INFLAMMATION RESEARCH 56, S446-S447	2007	
190	Synthesis and structure-activity relationships of [1, 2, 4] triazolo [3, 4-B][1, 3, 4] thiadiazole derivates as novel p38 mapk-inhibitors M Holm, **S Laufer** INFLAMMATION RESEARCH 56, S446-S446	2007	
189	Dendritic cell: T cell interactions and p38 mapkinase inhibition M Seed, E Johnson, M Burnet, V Holan, **S Laufer** INFLAMMATION RESEARCH 56, S433-S434	2007	
188	4-Aryl-5-heteroaryl-2-thio-imidazoles: warhead for a macrocycle-based drug targeting P Koch, **S Laufer** INFLAMMATION RESEARCH 56, S446-S446	2007	
187	p38 map kinase inhibitor prodrugs tropic for macrophages and neutrophils exert enhanced anti-inflammatory activity in IBD and collagen induced arthritis models JH Guse, M Burnet, S Luik, **S Laufer**, M Seed, V Holan, S Fiorucci INFLAMMATION RESEARCH 56, S434-S434	2007	
186	Validation of a diluted whole blood assay to evaluate cytokine release inhibitors S Luik, **S Laufer** INFLAMMATION RESEARCH 56, S446-S446	2007	
185	Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-pyridinylimidazole-type p38 mitogen-activated … B Kammerer, H Scheible, W Albrecht, CH Gleiter, **S Laufer** Drug metabolism and disposition 35 (6), 875-883	2007	
184	Synthesis, biological testing, and binding mode prediction of 6, 9-diarylpurin-8-ones as p38 MAP kinase inhibitors DRJ Hauser, T Scior, DM Domeyer, B Kammerer, **SA Laufer** Journal of medicinal chemistry 50 (9), 2060-2066	2007	
183	(2aRS, 3RS, 4aSR, 6aRS, 6bSR)-3-Hydroxy-2a, 3, 4a, 6, 6a, 6b-hexahydro-1, 4-dioxacyclopenta [cd] pentalen-2 (5H)-one C Peifer, D Schollmeyer, M Tschertsche, **S Laufer**	2007	

	Acta Crystallographica Section E: Structure Reports Online 63 (5), o2249-o2251		
182	3-(4-Fluorophenyl)-1-methyl-4-(4-pyridyl) quinolin-2 (1H)-one C Peifer, D Schollmeyer, K Kinkel, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 63 (5), o2457-o2459	2007	
181	2, 2-Dimethyl-N-[3-(3, 4, 5-trimethoxybenzoyl) pyridin-4-yl] propanamide K Kinkel, **S Laufer**, D Schollmeyer, C Peifer Acta Crystallographica Section E: Structure Reports Online 63 (4), o1887-o1889	2007	
180	rac-(3E, 3aR, 6aR)-3-(Hydroxymethylene)-3, 3a, 6, 6a-tetrahydro-2H-cyclopenta [b] furan-2-one C Peifer, D Schollmeyer, M Tschertsche, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 63 (4), o1551-o1553	2007	
179	From five-to six-membered rings: 3, 4-diarylquinolinone as lead for novel p38MAP kinase inhibitors C Peifer, K Kinkel, M Abadleh, D Schollmeyer, **S Laufer** Journal of medicinal chemistry 50 (6), 1213-1221	2007	
178	Pharmacokinetics of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor B Kammerer, H Scheible, W Albrecht, C Gleiter, **S Laufer** Drug Metabolism and Disposition	2007	
177	N-{(Z)-2-[1-(Triisopropylsilyl)-1H-indol-3-yl]-2-(triisopropylsilyloxy) vinyl}-2-(3, 4, 5-trimethoxyphenyl) acetamide C Peifer, R Selig, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 63 (3), o1266-o1268	2007	
176	(1aR, 2aS, 5aS, 5bS)-Perhydro-4H-oxireno [3, 4] cyclopenta [1, 2-b] furan-4-one C Peifer, M Tschertsche, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 63 (3), o1359-o1360	2007	
175	*In vitro* metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS B Kammerer, H Scheible, G Zurek, M Godejohann, KP Zeller, CH Gleiter, W Albrecht, **S Laufer** Xenobiotica 37 (3), 280-297	2007	
174	Ethyl (2, 3-dihydro-1H, 1′ H-2, 3′-biindol-1-yl) glyoxylate	2007	

	C Peifer, D Ott, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 63 (3), o1415-o1417		
173	4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl] pyridin-2 (1H)-one M Abadleh, C Peifer, K Kinkel, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 63 (3), o1423-o1425	2007	
172	Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase **S Laufer**, W Albrecht, M Burnet, HJ Gutke	2007	
171	Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[*b*,*e*]oxepin-11-ones and Dibenzo[*a*,*d*]cycloheptan-5-ones … **SA Laufer**, GM Ahrens, SC Karcher, JS Hering, R Niess Journal of medicinal chemistry 49 (26), 7912-7915	2006	
170	Profile and Molecular Modeling of 3-(Indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1*H*-pyrrole-2,5dione (**1**) as a Highly Selective VEGF-R2/3 Inhibitor C Peifer, A Krasowski, N Hämmerle, O Kohlbacher, G Dannhardt, F Trotzke, C Schächtele, **S Laufer** Journal of medicinal chemistry 49 (25), 7549-7553	2006	
169	Licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, reduces the progression of knee osteoarthritis (OA): A double blind, multicenter 2-year study using quantitative MRI. JP Pelletier, JP Raynauld, P Bias, **S Laufer**, B Haraoui, D Choquette, F Abram, E Vignon, J Martel-Pelletier ARTHRITIS AND RHEUMATISM 54 (12), 4119-4119	2006	
168	Stimulation of suicidal erythrocyte death by lipoxygenase inhibitor Bay-Y5884 E Shumilina, V Kiedaisch, A Akkel, P Lang, T Hermle, D Kempe, S Huber, T Wieder, **S Laufer**, F Lang Cellular Physiology and Biochemistry 18 (4-5), 233-242	2006	
167	Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten **S Laufer**, W Albrecht, C Greim, HG Striegel, K Tollmann	2006	
166	3, 4-Bis (4-fluorophenyl)-1, 2, 5-oxadiazole 2-oxide C Peifer, M Abadleh, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 62 (11), o4827-o4828	2006	
165	(4R)-4-Hydroxy-1-[(2S)-2-hydroxydodecyl]-l-proline monohydrate C Peifer, O Werz, D Poeckel, D Schollmeyer, **S Laufer**	2006	

	Acta Crystallographica Section E: Structure Reports Online 62 (11), o5138-o5140		
164	A concise and optimized four-step approach toward 2-(aryl-) alkylsulfanyl-, 4 (5)-aryl-, 5 (4)-heteroaryl-substituted imidazoles using alkyl-or arylalkyl thiocyanates **SA Laufer**, AJ Liedtke Tetrahedron letters 47 (40), 7199-7203	2006	
163	Inhibition of P38 kinase prevents T-cell responsiveness to allogenic dendritic cells E Johnson, **S Laufer**, V Holan, M Burnet, MP Seed INFLAMMATION RESEARCH 55, S118-S118	2006	
162	Development and optimization of a non-radioactive JNK3 assay C Peifer, S Luik, S Thuma, Y Herweh, **S Laufer** Combinatorial Chemistry & High Throughput Screening 9 (8), 613-618	2006	
161	4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl] pyridine C Peifer, M Abadleh, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 62 (9), o3647-o3649	2006	
160	4-[3-(4-Fluorophenyl)-5-isopropylisoxazol-4-yl] pyridine C Peifer, M Abadleh, D Schollmeyer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 62 (9), o3707-o3709	2006	
159	Development of a Microsphere-Based p38α MAP Kinase No-Wash Assay **S Laufer**, S Linsenmaier SLAS Discovery 11 (5), 528-536	2006	
158	Method for the production of 6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1h-pyrrolizin-5-ylacetic acid G Dannhardt, T Kammermeier, P Merckle, HG Striegel, **S Laufer** US Patent 7,078,535	2006	
157	4-(4-Fluorophenyl)-3-(4-pyridyl) quinolin-2 (1H)-one C Peifer, D Schollmeyer, R Selig, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 62 (7), o2648-o2650	2006	
156	Substituted isoxazole derivatives and their use in pharmaceutics **S Laufer**, HG Striegel, W Albrecht, K Tollmann US Patent App. 10/524,839	2006	
155	3-(4-Fluorophenyl)-4-(4-pyridyl) quinolin-2 (1H)-one C Peifer, D Schollmeyer, S Laudage, **S Laufer**	2006	

	Acta Crystallographica Section E: Structure Reports Online 62 (6), o2475-o2477		
154	Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity. M Moreau, C Boileau, J Martel-Pelletier, J Brunet, **S Laufer**, JP Pelletier The Journal of Rheumatology 33 (6), 1176-1183	2006	
153	Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cells MT Lindenmeyer, A Hrenn, C Kern, V Castro, R Murillo, S Müller, **S Laufer**, J Schulte-Mönting, B Siedle, I Merfort Bioorganic & Medicinal Chemistry 14 (8), 2487-2497	2006	
152	Discovery and development of LICOFELONE (ML3000) **S Laufer** PROSTAGLANDINS & OTHER LIPID MEDIATORS 79 (1-2), 161-161	2006	
151	Substituted isoxazoles as potent inhibitors of p38 MAP kinase **SA Laufer**, S Margutti, MD Fritz ChemMedChem: Chemistry Enabling Drug Discovery 1 (2), 197-207	2006	
150	Identification of urinary nucleosides by ESI-TOF-MS M Pelzing, T Zey, G Zurek, D Bullinger, A Frickenschmidt, **S Laufer**, B Kammerer LC GC NORTH AMERICA 24 (2), 14	2006	
149	Quantitative determination of piritramide in human plasma and urine by off-and on-line solid-phase extraction liquid chromatography coupled to tandem mass spectrometry R Kahlich, CH Gleiter, **S Laufer**, B Kammerer Rapid Communications in Mass Spectrometry: An International Journal Devoted …	2006	
148	High anti-inflammatory activity of harpagoside-enriched extracts obtained from solvent-modified super-and subcritical carbon dioxide extractions of the roots of Harpagophytum … M Günther, **S Laufer**, PC Schmidt Phytochemical Analysis: An International Journal of Plant Chemical and …	2006	
147	A novel naturally occurring tripyrrole with potential nuclease and anti-tumour properties pp 2480–2486 M Subramanian, R Chander, S Chattopadhyay, MT Lindenmeyer, A Hrenn, C Kern, V Castro, R Murillo, S Müller, **S Laufer**, J Schulte-Mönting, B Siedle, I Merfort Bioorganic & Medicinal Chemistry 14 (8)	2006	

146	Small molecular anti-cytokine agents G Wagner, **S Laufer** Medicinal research reviews 26 (1), 1-62	2006	
145	Small Molecule Inhibitors of p38 MAP Kinase C Peifer, G Wagner, **S Laufer** Current Topics in Medicinal Chemistry 6, 000-000	2006	
144	Complete Characterization of ML 3403 Metabolites from Liver Microsomes using ESI-Qq-TOF-MS and LC-SPE-cryo NMR/MS H Scheible, **S Laufer**, W Albrecht, CH Gleiter, G Zurek, M Spraul, M Godejohann, B Kammerer 54 th ASMS Conference Proceedings	2006	
143	New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase C Peifer, G Wagner, **S Laufer** Current topics in medicinal chemistry 6 (2), 113-149	2006	
142	The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa G Treiber, T Wex, A Link, M Vieth, **S Laufer**, P Malfertheiner Alimentary pharmacology & therapeutics 23 (1), 155-167	2006	
141	Identification of urinary nucleosides by ESI-TOF-MS D Bullinger, A Frickenschmidt, M Pelzing, G Zurek, **S Laufer**, T Zey, B Kammerer Advanstar Communications Inc.	2005	
140	Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes B Kammerer, R Kahlich, M Ufer, A Schenkel, **S Laufer,** CH Gleiter Analytical and bioanalytical chemistry 383, 909-917	2005	
139	Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review T Scior, A Guevara-García, P Bernard, QT Do, D Domeyer, **S Laufer** Mini reviews in medicinal chemistry 5 (11), 995-1008	2005	
138	The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage … JP Pelletier, C Boileau, M Boily, J Brunet, F Mineau, C Geng, P Reboul, **S Laufer**, D Lajeunesse, M Martel-Pelletier Arthritis research & therapy 7 (5), 1-12	2005	
137	Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof HG Striegel, **S Laufer**, K Tollmann, S Tries	2005	

	US Patent 6,936,632		
136	Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow H Ulbrich, O Soehnlein, X Xie, EE Eriksson, L Lindbom, W Albrecht, **S Laufer**, G Dannhardt Biochemical pharmacology 70 (1), 30-36	2005	
135	The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 … C Boileau, JP Pelletier, G Tardif, H Fahmi, **S Laufer**, M Lavigne, J Martel-Pelletier Annals of the rheumatic diseases 64 (6), 891-898	2005	
134	Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC–ITMS coupling B Kammerer, A Frickenschmidt, CE Müller, **S Laufer**, CH Gleiter, H Liebich Analytical and bioanalytical chemistry 382, 1017-1026	2005	
133	MALDI-TOF MS analysis of urinary nucleosides B Kammerer, A Frickenschmidt, CH Gleiter, **S Laufer**, H Liebich Journal of the American Society for Mass Spectrometry 16, 940-947	2005	
132	Cytokines and growth factors in the treatment of osteoarthritis: what could be the best disease modifying drugs J Martel-Pelletier, G Tardif, **S Laufer**, JP Pelletier Current Medicinal Chemistry-Anti-Inflammatory & Anti-Allergy Agents 4 (3 …	2005	
131	Naproxen induziert einen indirekten Cyclooxygenase-Lipoxygenase Shunt in der gastroduodenalen humanen Mucosa A Link, T Wex, M Vieth, **S Laufer**, P Malfertheiner, G Treiber Zeitschrift für Gastroenterologie 43 (05), P024	2005	
130	PGE2 in the regulation of programmed erythrocyte death PA Lang, DS Kempe, S Myssina, V Tanneur, C Birka, **S Laufer**, F Lang, T Wieder, SM Huber Cell Death & Differentiation 12 (5), 415-428	2005	
129	Achiral–chiral LC/LC–MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism B Kammerer, R Kahlich, M Ufer, **S Laufer**, CH Gleiter Analytical biochemistry 339 (2), 297-309	2005	
128	Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use **S Laufer**, K Tollmann, HG Striegel US Patent 6,878,738	2005	

127	Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. P Marcouiller, JP Pelletier, M Guévremont, J Martel-Pelletier, P Ranger, **S Laufer**, P Reboul The Journal of rheumatology 32 (4), 704-712	2005	
126	(3RS, 1SR)-3-Bromo-3-(1-phenylpropyl) chroman-2, 4-dione D Schollmeyer, B Kammerer, C Peifer, **S Laufer** Acta Crystallographica Section E: Structure Reports Online 61 (4), o868-o869	2005	
125	4-Pyridyl-and 2, 4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy HG Striegel, **S Laufer**, K Tollmann, S Tries US Patent 6,867,211	2005	
124	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors **SA Laufer**, DM Domeyer, TRF Scior, W Albrecht, DRJ Hauser Journal of medicinal chemistry 48 (3), 710-722	2005	
123	An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays **S Laufer**, S Thuma, C Peifer, C Greim, Y Herweh, A Albrecht, F Dehner Analytical biochemistry 1 (344), 135-137	2005	
122	Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position **SA Laufer**, W Zimmermann, KJ Ruff Journal of medicinal chemistry 47 (25), 6311-6325	2004	
121	Mass spectrometric pathway monitoring of secondary metabolites: systematic analysis of culture extracts of Streptomyces species B Kammerer, R Kahlich, **S Laufer**, SM Li, L Heide, CH Gleiter Analytical biochemistry 335 (1), 17-29		
120	Regulation of the expression of 5-lipoxygenase–activating protein/5-lipoxygenase and the synthesis of leukotriene B_4 in osteoarthritic chondrocytes: Role of … J Martel-Pelletier, F Mineau, H Fahmi, **S Laufer**, P Reboul, C Boileau, M Lavigne, JP Pelletier Arthritis & Rheumatism 50 (12), 3925-3933	2004	
119	Regulation of the expression of FLAP/5-LOX and synthesis of LTB4 in osteoarthritic chondrocytes: Role of TGF-beta and eicosanoids J Martel-Pelletier, F Mincau, H Fahmi, **S Laufer**, P Reboul, C Boileau, M Lavigne, JP Pelletier	2004	

	Arthritis and Rheumatism 50 (9), S286-S286		
118	Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow H Ulbrich, EE Eriksson, X Xie, O Soehnlein, L Lindbom, **S Laufer**, G Dannhardt ANNALS OF THE RHEUMATIC DISEASES 63, 137-137	2004	
117	NSAIDs and lipo-oxygenase/cyclo-oxygenase products modulte dendritic cell function S Fiorucci, A Di Lorenzo, S Farneti, M Barbanti, **S Laufer**, E Palazzini ANNALS OF THE RHEUMATIC DISEASES 63, 132-133	2004	
116	The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized … P Bias, A Buchner, B Klesser, **S Laufer** Official journal of the American College of Gastroenterology| ACG 99 (4), 611-618	2004	
115	2-Tiosubstituované imidazolové deriváty a ich použitie vo farmácii **S Laufer**, D Kotschenreuther, P Merckle, K Tollmann	2004	
114	The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and … JP Pelletier, C Boileau, J Brunet, M Boily, D Lajeunesse, P Reboul, **S Laufer**, J Martel-Pelletier Bone 34 (3), 527-538	2004	
113	Determination of (*R*)- and (*S*)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry B Kammerer, R Kahlich, M Ufer, **S Laufer**, CH Gleiter Rapid communications in mass spectrometry 18 (4), 458-464	2004	
112	Composto, composição farmacêutica, uso de pelo menos um composto, e, método para tratar distúrbios associados com um sistema imune perturbado **S Laufer**, D Kotschenreuther, P Merckle, K Tollmann, HG Striegel	2004	
111	Osteoarthritis therapy—are there still unmet needs? **S Laufer** Rheumatology 43 (suppl_1), i9-i15	2004	
110	Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis D Lajeunesse, J Martel-Pelletier, JC Fernandes, **S Laufer,** JP Pelletier Annals of the rheumatic diseases 63 (1), 78-83	2004	

109	Combined approach for analysis of biological activity of compounds MA Grishina, VA Potemkin, KM Mikuchina, GV Pozhilenkova, **S Laufer** Biomeditsinskaya khimiya 50 (app1), 68-76	2004	
108	The regulation of human metalloprotease-13 by licofelone, an inhibitor of cyclooxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition … C Boileau, JP Pelletier, F Mineau, G Tardif, H Fahmi, **S Laufer**, M Lavigne, J Martel-Pelletier OSTEOARTHRITIS AND CARTILAGE 12, S100-S100	2004	
107	Genetic algorithm for molecular 3D drug design VA Potemkin, MA Grishina, GV Pozhilenkova, KM Mikuchina, **S Laufer** Biomeditsinskaya khimiya 50 (app1), 42-48	2004	
106	COX-3—a virtual pain target in humans? JM Schwab, T Beiter, JU Linder, **S Laufer**, JE Schulz, R Meyermann, HJ Schluesener The FASEB journal 17 (15), 2174-2175	2003	
105	Inhibition of human MMP-13 expression by licofelone, a dual inhibitor of cyclooxygenase/5-lipoxygenase in human osteoarthritic (OA) chondrocytes. C Boileau, JP Pelletier, **S Laufer**, P Ranger, J Martel-Pelletier ARTHRITIS AND RHEUMATISM 48 (9), S283-S283	2003	
104	Role of eicosanoids in structural degradation in osteoarthritis **S Laufer** Current opinion in rheumatology 15 (5), 623-627	2003	
103	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes **SA Laufer**, GK Wagner, DA Kotschenreuther, W Albrecht Journal of medicinal chemistry 46 (15), 3230-3244	2003	
102	Study of cross talking between leukotriene and prostaglandin synthetic pathways in human OA synovial membranes: Mechanisms of regulation P Reboul, P Marcouiller, **S Laufer**, J Martel-Pelletier, JP Pelletier ANNALS OF THE RHEUMATIC DISEASES 62, 114-115	2003	
101	Selective COX-2 inhibitors, but not licofelone, a LOX/COX inhibitor, inhibit anti-adhesive activity of aspirin S Fiorucci, A Mencarelli, E Distrutti, **S Laufer**, M Barbanti, E Palazzini, A Morelli, JL Wallace ANNALS OF THE RHEUMATIC DISEASES 62, 116-116	2013	

100	Inhibition of human MMP-13 expression by licofelone, a dual inhibitor of cyclooxygenases/5-lipoxygenase in human osteoarthritic chondrocytes C Boileau, JP Pelletier, **S Laufer**, P Ranger, J Martel-Pelletier ANNALS OF THE RHEUMATIC DISEASES 62, 262-263	2003	
99	International Conference on Inflammopharmacology–VIII Side-Effects of Anti-Inflammatory Drugs Symposium **S Laufer** Expert Opinion on Investigational Drugs 12 (7), 1239-1241	2003	
98	Identification of Regioisomers in a Series of N-Substituted Pyridin-4-yl Imidazole Derivatives by Regiospecific Synthesis, GC/MS, and ^{1}H NMR GK Wagner, D Kotschenreuther, W Zimmermann, **SA Laufer** The Journal of organic chemistry 68 (11), 4527-4530	2003	
97	COX-3: just another COX or the solitary elusive target of paracetamol? JM Schwab, HJ Schluesener, **S Laufer** The Lancet 361 (9362), 981-982	2003	
96	Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo. I Wagner, C Greim, **S Laufer**, L Heide, CH Gleiter Clinical pharmacology and therapeutics 73 (3), 272-274	2003	
95	NO-Donors. Part 7. Synthesis and Cyclooxygenase Inhibitory Properties of N-and S-Nitrooxypivaloyl-cysteine Derivatives of Naproxen—A Novel Type of NO-NSAID. RE Kartasasmita, **S Laufer**, J Lehmann ChemInform 34 (4), no-no	2003	
94	Inflammation and rheumatic diseases. The molecular basis of novel therapies F Calanni, **S Laufer** Biochemistry and mediators of inflammation. Georg Thieme Verlag, Stuttgart	2003	
93	Inflammation and Rheumatic Diseases: The molecular basis of novel therapies **S Laufer**, S Gay, K Brune Georg Thieme Verlag	2003	
92	Biochemistry and mediators of inflammation F Calanni, **S Laufer** Inflammation and Rheumatic Diseases. The Molecular Basis of Novel Therapies. Georg Thieme Verlag	2003	

91	LETTERS TO THE EDITOR-Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor a or interleukin 1b release in vitro and ex vivo I Wagner, C Greim, **S Laufer**, L Heide, CH Gleiter Clinical Pharmacology and Therapeutics 73 (3), 272-273	2003	
90	Antitubercular Isoniazid and Drug Resistance of *Mycobacterium tuberculosis* — A Review T Scior, I Meneses Morales, SJ Garcés Eisele, D Domeyer, **S Laufer** Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry 335 (11-12), 511-525	2002	
89	An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying … **S Laufer**, C Greim, T Bertsche Osteoarthritis and cartilage 10 (12), 961-967	2002	
88	NO-Donors (VII [1]): Synthesis and Cyclooxygenase Inhibitory Properties of *N*-and *S*-Nitrooxypivaloyl-cysteine Derivatives of Naproxen — A Novel Type of NO … RE Kartasasmita, **S Laufer**, J Lehmann Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry 335 (8) 363-366	2002	
87	Imidazole inhibitors of cytokine release: probing substituents in the 2 position **SA Laufer**, HG Striegel, GK Wagner Journal of medicinal chemistry 45 (21), 4695-4705	2002	
86	Discovery and development of LICOFELONE (ML3000) **S Laufer**, S Tries, HG Striegel, P Bias, A Buchner EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 58 (7), S100-S100	2002	
85	2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie **S Laufer**, D Kotschenreuther, P Merckle, K Tollmann, HG Striegel	2002	
84	2-arylalkylthio-imidazoles, 2-arylalkenyl-thio-imidazoles and 2-arylalkinyl-thio-imidazoles as anti-inflammatory substances and substances inhibiting the release of cytokine **S Laufer**, HG Striegel, K Neher US Patent 6,432,988	2002	
83	Process for preparing 6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1H-pyrrolizin-5-yl-acetic acid T Kammermeier, **S Laufer**, P Merckle, HG Striegel US Patent 6,417,371	2002	

82	Ones, Thiones, and *N*-Oxides: An Exercise in Imidazole Chemistry **S Laufer**, G Wagner, D Kotschenreuther Angewandte Chemie International Edition 41 (13), 2290-2293	2002	
81	One, Thione und N-Oxide: ein allgemeiner Zugang zu Imidazolderivaten **S Laufer**, G Wagner, D Kotschenreuther Angewandte Chemie 114 (13), 2408-2411	2002	
80	Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis … C Boileau, J Martel-Pelletier, JY Jouzeau, P Netter, F Moldovan, **S Laufer,** S Tries, JP Pelletier The Journal of Rheumatology 29 (7), 1446-1453	2002	
79	Study of the role of leukotriene B_4 in abnormal function of human subchondral osteoarthritis osteoblasts: Effects of cyclooxygenase and/or 5-lipoxygenase inhibition Y Paredes, F Massicotte, JP Pelletier, J Martel-Pelletier, **S Laufer**, D Lajeunesse Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 46 (7) 1804-1812	2002	
78	From imidazoles to pyrimidines: new inhibitors of cytokine release **SA Laufer**, GK Wagner Journal of medicinal chemistry 45 (13), 2733-2740	2002	
77	Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers CA Klaas, G Wagner, **S Laufer**, S Sosa, R Della Loggia, U Bomme, HL Pahl, I Merfort Planta medica 68 (05), 385-391	2002	
76	Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants … W He, JP Pelletier, J Martel-Pelletier, **S Laufer**, JA Di Battista The Journal of Rheumatology 29 (3), 546-553	2002	
75	Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity S Tries, **S Laufer**, P Radziwon, HK Breddin Inflammation Research 51, 129-134	2002	
74	The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2 S Tries, W Neupert, **S Laufer** Inflammation Research 51, 135-143	2002	

73	Neue NSAR: Was bietet die Zukunft? **S Laufer** Pharmazie in unserer Zeit 31 (2), 164-169	2002	
72	Synthesis of IL-1b, TNF-a, and Interstitial Collagenase (MMP-1) Is Eicosanoid Dependent in Human OA Synovial Membrane Explants: Interactions with Antiinflammatory Cytokines W He, JP Pelletier, J Martel-Pelletier, **S Laufer**, JA DiBattista Journal of Rheumatology 29 (3), 546-553	2002	
71	Biochemie und Mediatoren der Entzündung **S Laufer** Rheumatische Erkrankungen und Entzündung: Von den molekularen Grundlagen zur medikamentösen Therapie, Georg Thieme Verlag	2002	
70	Rheumatische Erkrankungen und Entzündung: von den molekularen Grundlagen zur medikamentösen Therapie; 26 Tabellen **S Laufer**, S Gay, K Brune Georg Thieme Verlag	2002	
69	Osteoarthritis and Cartilage-Study of the Role of Leukotriene B4 in Abnormal Function of Human Subchondral Osteoarthritis Osteoblasts: Effects of Cyclooxygenase and/or 5 … Y Paredes, F Massicotte, JP Pelletier, J Martel-Pelletier, **S Laufer**, D Lajeunesse Arthritis and Rheumatism 46 (7), 1804-1812	2002	
68	Neue und zukünftige Therapieansätze **S Laufer** Laufer, S., Gay, G., Brune K.: Rheumatische Erkrankungen und Entzündung. Georg Thieme Verlag	2002	
67	In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1β … DV Jovanovic, JC Fernandes, J Martel-Pelletier, FC Jolicoeur, P Reboul, **S Laufer**, S Tries, JP Pelletier Arthritis & Rheumatism 44 (10), 2320-2330	2001	
66	The in vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase-1 and interleukin-1 … JP Pelletier, JC Fernandes, FC Jolicoeur, P Reboul, S Laufer, S Tries, J Martel-Pelletier ARTHRITIS AND RHEUMATISM 44 (9), S307-S307	2001	
65	Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. RE Gay, M Neidhart, F Pataky, S Tries, **S Laufer**, S Gay The Journal of Rheumatology 28 (9), 2060-2065	2001	

64	Role of leukotriene B-4 in abnormal function of osteoarthritic osteoblasts. D Lajeunesse, Y Paredes, F Massicotte, J Martel-Pelletier, **S Laufer**, JP Pelletier ARTHRITIS AND RHEUMATISM 44 (9), S308-S308	2001	
63	Discovery and development of ML3000 **S Laufer** Inflammopharmacology 9, 101-112	2001	
62	The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase S Tries, **S Laufer** Inflammopharmacology 9, 113-124	2001	
61	Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept F Celotti, **S Laufer** Pharmacological Research 43 (5), 429-436	2001	
60	Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2-(6-Methoxy-2-naphthyl) propanoic Acid (Naproxene) Derivatives AH Abadi, **S Laufer**, J Lehmann Archiv der Pharmazie 334 (3), 104-106	2001	
59	Antiinflammatorische oxo-und hydroxyderivate von pyrrolizinen und deren anwendung in der pharmazie **S Laufer**, K Neher, HG Striegel	2001	
58	Effects of natural products containing acylresorcinol partial structures on cyclooxygenases and 5-lipoxygenase F Bracher, J Krauss, **S Laufer** Pharmazie 56 (5)	2001	
57	Copyright WILEY-VCH Verlag GmbH, D-69451 Weinheim, 2001. Supporting Information for Angew. Chem. Int. Ed. Z18173 **S Laufer**, G Wagner, D Kotschenreuther	2001	
56	Osteoarthritis and Cartilage-In Vivo Dual Inhibition of Cyclooxygenase and Lipoxygenase by ML-3000 Reduces the Progression of Experimental Osteoarthritis: Suppression of … DV Jovanovic, JC Fernandes, J Martel-Pelletier, FC Jolicoeur, P Reboul, **S Laufer**, S Tries, JP Pelletier Arthritis and Rheumatism 44 (10), 2320-2330	2001	
55	Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? G Dannhardt, **S Laufer** Current Medicinal Chemistry 7 (11), 1101-1112	2000	

54	A NOVEL AND VERSATILE SYNTHETIC APPROACH TOWARDS NI-SUBSTITUTED IMIDAZOLE DERIVATIVES D Kotschenreuther, **S Laufer** ARCHIV DER PHARMAZIE 333, 43-43	2000	
53	In-vitro screening assay to evaluate cytokine release inhibitors C Donat, **S Laufer** ARCHIV DER PHARMAZIE 333, 15-15	2000	
52	TOWARDS NEW INHIBITORS OF CYTOKINE RELEASE G Wagner, **S Laufer** ARCHIV DER PHARMAZIE 333, 97-97	2000	
51	A!-anellated pyrrole derivatives and their use in pharmacology **S Laufer**, HG Striegel, G Dannhardt US Patent 5,958,943	1999	
50	a!-Annelated pyrrole derivatives and pharmaceutical use thereof **S Laufer**, HG Striegel, G Dannhardt US Patent 5,942,535	1999	
49	A!-annellated pyrrole derivatives and their use in pharmacology **S Laufer**, HG Striegel, G Dannhardt US Patent 5,939,415	1999	
48	Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors **S Laufer**, P Zechmeister, T Klein Inflammation research 48, 133-138	1999	
47	Anti-inflammatory activity of myricetin-3-O-β-D-glucuronide and related compounds A Hiermann, HW Schramm, **S Laufer** Inflammation research 47, 421-427	1998	
46	Uricosurisch wirksame Metabolite des Benzbromarons **S Laufer**, J Manner, S Tries, V Luckow, P Arnold SCIENTIA PHARMACEUTICA 66, S76-S76	1998	
45	The effects of ML 3000 on antigen-induced responses in sheep WM Abraham, **S Laufer**, S Tries Pulmonary pharmacology & therapeutics 10 (3), 167-173	1997	
44	Bioequivalence evaluation of two flutamide preparations in healthy female subjects. K Doser, R Guserle, R Kramer, **S Laufer**, K Lichtenberger Arzneimittel-forschung 47 (2), 213-217	1997	

43	Synthesis and evaluation of a novel series of pyrrolizine derivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors **S Laufer**, HG Striegel, K Neher, P Zechmeister, C Donat, K Stolingwa, S Baur, S Tries, T Kammermeier, G Dannhardt, W Kiefer Archiv der Pharmazie 330 (9-10), 307-312	1997	
42	Synthesis and biological identification of the acyl glucuronide of the antiinflammatory drug ML-3000 A Kirschning, M Ries, S Domann, W Martin, W Albrecht, P Arnold, **S Laufer** Bioorganic & Medicinal Chemistry Letters 7 (7), 903-906	1997	
41	Efficient Synthesis of New 2-Cycloalk (en) ylpropanoic Acid Derivatives—Medium and Large Rings as Bioisosteres of Alkylphenyl Moieties? B Greve, P Imming, **S Laufer** Angewandte Chemie International Edition in English 35 (11), 1221-1223	1996	
40	Effiziente Synthese neuer 2-Cycloalk (en) yl-propansäure-Derivate–mittlere und große Ringe als Bioisostere von Alkylphenylresten? B Greve, P Imming, **S Laufer** Angewandte Chemie 108 (11), 1312-1314	1996	
39	Regioisomeric 5 (3)-aminomethyl-3 (5)-phenylisoxazoles: synthesis, spectroscopic discrimination, and muscarinic activity. G Dannhardt, G Lambrecht, **S Laufer**, E Mutschler, J Schweiger Archiv der Pharmazie 328 (5), 437-443	1995	
38	Studies on the in vitro and in vivo genotoxicity of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid A Heidemann, S Tries, **S Laufer**, J Augustin Arzneimittel-Forschung 45 (4), 486-490	1995	
37	Distribution and excretion of [14C]-labelled [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-[2'-14C]-acetic acid in rats. HP Deigner, CE Freyberg, **S Laufer** Arzneimittel-forschung 45 (3), 272-276	1995	
36	General pharmacology of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals. DR Algate, J Augustin, PR Atterson, DJ Beard, CM Jobling, **S Laufer**, PL Munt, S Tries Arzneimittel-forschung 45 (2), 159-165	1995	
35	Acute and chronic anti-inflammatory properties of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.	1995	

	S Laufer, S Tries, J Augustin, R Elsässer, W Albrecht, R Guserle, DR Algate, PR Atterson, PL Munt Arzneimittel-forschung 45 (1), 27-32		
34	In-vitro test system for the evaluation of dual cyclooxygenase and 5-lipoxygenase inhibitors **S Laufer**, K Neher, B Bayer, J Homann, E Reutter, S Tries Pharmaceutical and Pharmacological Letters 5 (4), 166-169	1995	
33	Regioisomeric 3-, 4-and 5-aminomethyl isoxazoles: synthesis and muscarinic activity G Dannhardt, W Kiefer, G Lambrecht, **S Laufer**, E Mutschler, J Schweiger, HG Striegel European journal of medicinal chemistry 30 (11), 839-850	1995	
32	ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury JL Wallace, L Carter, W McKnight, S Tries, **S Laufer** European journal of pharmacology 271 (2-3), 525-531	1994	
31	Gastrointestinal tolerance of [2, 2-dimethyl-6-(4-chlorophenyl-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the rat. **S Laufer**, S Tries, J Augustin, R Elsässer, DR Algate, PR Atterson, PL Munt Arzneimittel-forschung 44 (12), 1329-1333	1994	
30	P59 Diarylpyrrolizines; dual inhibitors of CO and 5-LO **S Laufer**, S Tries, J Augustin European Journal of Pharmaceutical Sciences 2 (1-2), 133	1994	
29	(6, 7-Diaryldihydropyrrolizin-5-yl) acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase **SA Laufer**, J Augustin, G Dannhardt, W Kiefer Journal of medicinal chemistry 37 (12), 1894-1897	1994	
28	Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. **S Laufer**, S Tries, J Augustin, G Dannhardt Arzneimittel-forschung 44 (5), 629-636	1994	
27	Duale Hemmstoffe der Cyclooxygenase und 5-Lipoxygenase; ein neuer Ansatz zur Entwicklung nebenwirkungsarmer NSAR **S Laufer**, S Tries, J Augustin, G Dannhardt SCIENTIA PHARMACEUTICA 62, 167-167	1994	
26	Hypertensive effects and structure-activity relationships of 5-omega-aminoalkyl isoxazoles. G Dannhardt, P Dominiak, **S Laufer** Arzneimittel-forschung 43 (4), 441-444	1993	

25	5-(β-Aminoethyl) aminoisoxazoles with Hypertensive Activity: Synthesis and Screening of Isoxazolopyrazines and Isoxazolodiazepines. G DANNHARDT, P DOMINIAK, **S LAUFER** ChemInform 22 (28), no-no	1991	
24	5-((β-Aminoethyl) amino) isoxazoles with Hypertensive Activity: Synthesis and Screening of Derivatives with Partially Rigid C-5 Side Chains and Heterocycles at the ω-Position … G Dannhardt, P DOMINIAK, **S LAUFER** ChemInform 22 (2), no-no	1991	
23	Hypertensiv wirksame 5-(β-Aminoethyl) aminoisoxazole: Synthese und Prüfung von Isoxazolopyrazinen und Isoxazolodiazepinen G Dannhardt, P Dominiak, **S Laufer** Archiv der Pharmazie 324 (3), 141-148	1991	
22	Hypertensive acting 5-(beta-aminoethyl) aminoisoxazoles: synthesis and screening of derivatives with with partially rigid C-5 side chains and omega-position heterocyclics G Dannhardt, P Dominiak, **S Laufer** Archiv der Pharmazie 323 (9), 571-578	1990	
21	Hypertensive action of 5-(omega-aminoalkyl) aminoisoxazole: synthesis and testing of compounds with a sulfamide or carboxyl group on the end of side chain G Dannhardt, P Dominiak, **S Laufer** Archiv der Pharmazie 323 (8), 517-519	1990	
20	5-(OMEGA-AMINOALKYL) AMINOISOXAZOLES WITH HYPERTENSIVE ACTIVITY-SYNTHESIS AND SCREENING OF COMPOUNDS WITH A SULFAMIDE OR CARBOXYL FUNCTION AT THE END OF THE SIDE-CHAIN G DANNHARDT, P DOMINIAK, **S LAUFER** ARCHIV DER PHARMAZIE 323 (8), 517-519	1990	
19	Ring Transformations of 2-Phenacylidenimidazolidines: Synthesis of 5-(β-Aminoethyl) anilinopyrazoles and 2-Acyl-3-(β-aminoethyl) aminothiophenes. G Dannhardt, **S Laufer** ChemInform 21 (7), no-no	1990	
18	Hypertensiv wirksame 5-(ω-Aminoalkyl) aminoisoxazole: Synthese und Prüfung von Verbindungen mit einer Sulfamid-oder Carboxyl-Gruppe am Ende der Seitenkette G Dannhardt, P Dominiak, **S Laufer** Archiv der Pharmazie 323 (8), 517-519	1990	
17	Hypertensiv wirksame 5-(β-Aminoethyl) aminoisoxazole: Synthese und Prüfung von Derivaten mit teilrigidisierter C-5-Seitenkette bzw. ω-ständigem Heterocyclus	1990	

	G Dannhardt, P Dominiak, **S Laufer** Archiv der Pharmazie 323 (9), 571-578		
16	A New Synthesis of 3, 4-Diaryl-5-oxo-4, 5-dihydroisoxazoles and Their Transformation to 5-(N-(ω-Aminoalkyl) amino) isoxazoles and 5-(2-Aminoethylthio) isoxazoles. G Dannhardt, **S Laufer**, I Obergrusberger ChemInform 20 (37), no-no	1989	
15	Ring Transformation of 2-Phenacylidenimidazolidines into 5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazoles. G Dannhardt, **S Laufer** ChemInform 20 (23), no-no	1989	
14	5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazole durch Ringtransformation von 2-Phenacylidenimidazolidinen G Dannhardt, **S Laufer** Synthesis 1989 (01), 12-15	1989	
13	Eine neue Synthese für 3, 4-Diaryl-5-oxo-4, 5-dihydroisoxazole und ihre Überführung in 5-[N-(ω-Aminoalkyl) amino) isoxazole und 5-(2-Aminoethylthio) isoxazole G Dannhardt, **S Laufer**, I Obergrusberger Synthesis 1989 (04), 275-280	1989	
12	HPLC determination of etofenamate and flufenamic acid in biological material. G Dannhardt, **S Laufer**, M Lehr Clinical chemistry 34 (12), 2580-2581	1988	
11	PREPARATION AND CARDIOVASCULAR ACTIVITY OF 5-OMEGA-AMINO-ALKYL (-HETEROALKYL) ISOXAZOLENE G DANNHARDT, P DOMINIAK, **S LAUFER** ARCHIV DER PHARMAZIE 321 (9), 576-576	1988	
10	Enaminodiesters and Monoesters with a Semicyclic C□ C-Bond of the Pyrrolidine and Imidazolidine Series G Dannhardt, **S Laufer**, K Ziereis Archiv der Pharmazie 321 (7), 429-430	1988	
9	Unselective COX Inhibitors **SA Laufer**	1988	
8	TÍTULO DO TRABALHO: TRITERPENÓIDE ISOLADO DAS PARTES AÉREAS DE Senecio selloi Spreng. DC.: AVALIAÇÃO DAS ATIVIDADES ANTIINFLAMATÓRIA E ANESTÉSICA GERAL. GNS DA SILVA, MA DA CUNHA, B BALDISSEROTTO, **S LAUFER**, CA MALLMANN, BM HEINZMANN		

7	Identification of Urinary Nucleosides D Bullinger, A Frickenschmidt, M Pelzing, T Zey, G Zurek, **S Laufer**, B Kammerer		
6	Structure and Metabolic Function of COX-1 **SA Laufer**		
5	PHYTOCHEMICAL AND BIOLOGICAL STUDIES OF THE BARK FROM PARAPIPTADENIA RIGIDA CA Schmidt, M Fronza, M Goettert, R Murillo, V Brecht, B Heinzmann, **S Laufer**, I Merfort		
4	COX-3Oa virtual pain target in humans? J SCHWAB, T BEITER, JU LINDER, **S LAUFER**, JE SCHULZ, R MEYERMANN, HJ SCHLUESENER		
3	p38 MAP-KINASE INHIBITORS AND THEIR CYP-450 INTERFERENCE: AN OPTIMIZATION K Ruff, D Kotschenreuther, **S Laufer**		
2	Small Molecule Inhibitors OF Cytokine Release Bioisosteric Replacement MD Fritz, **S Laufer**		
1	Covalent Inhibitors re-invented P Koch, F Muth, M Günther, M Juchum, M Forster, D Rauh, S Knapp, **SA Laufer**		
	Artikel 1–633		